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Human GPR35 (hGPR35), a recently deorphanized Class A G-protein coupled receptor, 
has been shown to exhibit prominent expression in immune and gastrointestinal tissues, with 
additional expression in pancreatic islets, skeletal muscle, lung tissue, and the dorsal root 
ganglion. The rat GPR35 (rGPR35) analog, which has 72% sequence identity with human 
GPR35, has been shown to have expression in similar tissues as with human GPR35. GPR35 has 
been suggested to be involved in metabolism, heart failure, inflammation, asthma, a mental 
retardation syndrome associated with the deletion on 2q37.3, type II diabetes, as well as gastric 
cancer formation, making GPR35 a potential target for the treatment of multiple diseases.  
Both zaprinast, the well characterized cGMP-PDE inhibitor, and pamoic acid, a 
compound which the FDA has classified as an inactive compound, act as agonists at GPR35. 
However, interesting species differences have been found with these agonists and key mutations 
have also revealed differences between these two ligands. Pamoic acid is considerably lower in 
potency in rat GPR35, while zaprinast has increased efficacy in rat GPR35. Further, mutation 
studies suggest an increase in the potency of zaprinast in a human GPR35 R6.58A mutation.  
Pamoic acid, on the other hand shows similar potency to wild-type in this same mutant.  
To probe the molecular origins of these differences, three separate homology models, an 
active (R*) hGPR35, an R* hGPR35 R6.58A(240) mutant, and an R* rGPR35 model, were 
constructed and docking studies were performed with the aforementioned ligands. These studies 
revealed that the change in residue 5.43 (P5.43 in human; S5.43 in rat) alters the shape of the 
binding pocket for pamoic acid.  In addition, arginines which contribute significantly to the 
interaction of pamoic acid in hGPR35 (R6.58 and R7.32) become uncharged residues (Q6.58 and 
 
 
S7.32) in rat GPR35. The increase of the potency of zaprinast in the hGPR35 R6.58A mutant 
receptor is due to the loss of bulk at position 6.58 (R6.58(240)→ A6.58(240)), that allows for 
additional interactions with the ligand. The statistically equivalent potencies of pamoic acid for 
the wild-type and R6.58A(240) mutant hGPR35 receptors is due to the isoenergetic interchange 
of the direct interaction residue  R6.58(240) with R7.32(255) in the R6.58(240)A mutant.   
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CHAPTER I 
 
INTRODUCTION 
 
 
G-Protein coupled receptors (GPCRs) are the largest class of integral membrane proteins 
that are both involved in signal transduction and are activated by extracellular signals [1].  The 
activation of GPCRs is known to invoke a series of downstream effects, often referred to as signal 
cascades, which are involved in a nearly innumerable number of cellular actions. These actions 
include, but are not limited to, protein expression patterns, translational regulation, and general 
cell metabolism. The known endogenous ligands for GPCRs are incredibly diverse, including 
hormones, peptide neurotransmitters, chemokines, ions, and phospholipids [1]. The direct 
involvement of GPCRs in multiple key physiological processes, their activation by extracellular 
signaling, and their ligand diversity, makes GPCRs ideal targets for pharmaceuticals.   
All GPCRs are predicted to share a similar topology, which has been exemplified in the 
published crystal structures of GPCRs Rhodopsin [2-5], Opsin [6], β-2 adrenergic receptor (β2-
AR) [7-8], A2A adenosine receptor (A2-AR) [9], dopamine D3 receptor (D3-R) [10], and the 
CXCR4 chemokine receptor (CXCR4-R) [11]. A GPCR’s topology can be separated into four 
components:  an extracellular N-terminus, seven transmembrane α-helices (TMH) creating a 
closed bundle, intra- (IC) and extracellular (EC) loops connecting the transmembrane α-helices, 
and an intracellular C-terminus that is initially a short helical segment, that is aligned parallel 
with the phospholipid head groups of the bilayer, known as helix 8 (Hx 8). The crystal structures 
published to date suggest that GPCR ligands are bound in pockets formed by the TMHs and that 
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the residues binding these ligands are found in these pockets and in adjacent loops. The 
similarities found between different class “A” GPCRs, in both crystal structures and in other 
biophysical data, suggest that many features may be nearly universal within all similarly classed 
GPCRs. This doctrine leads to the possibility of creating homology models of other, less 
understood GPCRs by paralleling some of these universal similarities.  
Throughout this document,  the amino acid numbering scheme proposed by Ballesteros 
and Weinstein [12] is used. In this numbering system, the most highly conserved amino acid in 
each TMH is assigned a locant of .50, and the number preceding this is representative of the 
TMH number. The amino acids immediately preceding and following the .50 residue are 
numbered .49 and .51, respectively. An example of numbering, using the β2-AR sequence, is 
assigning the highly conserved proline on TMH7 a number of 7.50(323), with the number in 
brackets representing the absolute sequence number. The amino acids preceding and following 
P7.50(323) are N7.49(322) and L5.51(324) respectively. This numbering scheme applies to the 
amino acids in the TMH region exclusively; the N- and C-terminus, as well as the loop residues, 
are numbered using absolute sequence numbers only.  
The description of the relative topology of a protein requires the definitions of both the 
side chain and the backbone dihedral torsional angles. Each dihedral is a rotatable bond, which is 
defined by the relative position of the atoms directly connected to the atoms of interest. There are 
three defined backbone dihedrals of amino acid chains: Φ (phi), Ψ (psi) and ω (omega). The Φ, 
Ψ, and ω dihedral angle rotate about the bond between the N-Cα, Cα –C(O), and C(O)-N atoms, 
respectively (Figure 1A).  Side chain dihedrals are designated with a χ followed by an integer 
between 1 and 5, which defines the involved atoms. An example of lysine is depicted in figure 
1B, which defines χ1, 2, 3, 4, 5 as the rotatable bonds between the atoms Cα – Cβ, Cβ – Cγ, Cγ – 
Cδ, and Cδ – Cε, respectively. As previously mentioned, the measurement of each side chain 
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dihedral is defined not by the positions of atoms directly involved in the bond of interest, but by 
the relative positions of the atoms which are connected to these atoms. The example, shown in 
Figure 2, depicts the three low energy conformers of the χ1 dihedral: gauche+ (g+), gauche- (g-), 
and trans.   The numerical value of the χ1 dihedral is defined by the angle made by the relative 
positions of an amino acid’s backbone nitrogen (N) and its Cγ or Oxygen, depending on the amino 
acid. The convention is to assign a value for the dihedral angle by calculating the degrees of 
rotation required to eclipse the two atoms, with clockwise and counterclockwise having positive 
and negative values, respectively. The ideal value of each rotamer is defined as: g+ = -60°, g- = 
+60°, and trans = 180°. In a α-helix, a χ1 = g+ or trans conformation is the preferred low energy 
state in the majority of amino acids, with the occasional adoption of the χ1 = g- rotamer by the 
residues serine and threonine.  
 
 
Figure 1. An example of backbone (Φ, Ψ and ω) and sidechain dihedrals. (A) An illustration of the 
backbone dihedrals Φ, Ψ and ω, using an amino acid skeleton. (B) The sidechain of the amino acid 
lysine, with labeled heteroatoms and defined sidechain dihedrals χ1 - χ5. 
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Figure 2.  A depiction of the three low energy conformers of the χ1 dihedral. The low energy 
conformers are (A) gauche+ (g+), (B) gauche- (g-), and (C) trans. 
 
 
Existing knowledge concerning GPCR activation comes mostly from biophysical studies 
involving the prototypical GPCRs, rhodopsin and the β2-AR.  The canonical transition from an 
inactive (R) to an active (R*) GPCR bundle involves a series of rotameric changes in key, 
conserved residues, which translate to much larger structural changes in the TMHs.  The most 
dramatic structural change associated with the activation of β2-AR and rhodopsin is the general 
rotation and straightening of TMH6 about the highly conserved CWXP hinge region [13-21].  In 
rhodopsin, this change in TMH6 is suggested to cause a net movement of the Cα of E6.30(247) 
approximately 6 Å away from the intracellular end of TMH3 [18], which is assumed to break the 
salt bridge between E6.30(247) and D3.50(135). This breaking of the interaction between R3.50 
and a polar or negatively charged residue on the intracellular end of TMH6 is presumed to be one 
of the major features of GPCR activation. This general movement of TMH6 has also been 
suggested to occur during activation in the M3 muscarinic acetylcholine receptor in in situ 
disulfide crosslinking studies [22-23], further supporting its universality.   
A highly conserved tryptophan within the ligand binding pocket on TMH6, W6.48, is 
suggested to be a toggle switch residue related to activation.  The rotameric χ1 change of W6.48 
is suggested to occur during the R to R* transition.  Multiple spectroscopic studies have 
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suggested that W6.48 changes both position and interaction partners in rhodopsin [14, 24-25] and 
in the β2-AR [26] during agonist-dependent activation, suggesting a rotameric change associated 
with activation. The rhodopsin crystal structures [2-4] shows that the beta-ionone ring of the 
covalently bound ligand, 11–cis-retinal, is proximal to W6.48(265), which constrains it in a χ1 = 
g+ conformation. When activated by light, the 11-cis-retinal isomerizes, moving the beta-ionone 
ring away from W6.48, relieving the side-chain’s torsional constraint [27] which allows for a 
rotameric χ1 change.  In conjunction with spectroscopic studies, this suggests that the χ1 rotamer 
of W6.48(265) changes from g+ to trans during the activation of rhodopsin. Crystal structures of 
both β2-AR [7] and A2-AR [9] also suggest that 6.48 adopts a χ1 = g+ conformation in its 
inactive state, suggesting that the χ1 rotamer change from g+ to trans is synonymous with GPCR 
activation. Mutation studies have shown that the mutation of 6.48 to alanine significantly reduces 
constitutive activity and agonist-induced receptor activation in class A GPCRs GPR119, GPR39, 
β2-AR, and ghrelin without affecting ligand binding [28], further implicating this residue’s 
importance in activation. Other residues are suggested to be involved with regulating this 
rotameric change in 6.48. An example is F3.36(200) in CB1, which has been suggested in 
modeling studies by the Reggio lab to act as a regulatory residue which transitions from a trans to 
a g+ χ1 rotameric state during activation [29]. While in a χ1 = trans rotameric state, F3.36(200) 
constrains W6.48(356) in a χ1= g+ rotamer, impeding activation.  F3.36A(200) mutation studies 
have shown an increase in constitutive activity, suggested that F3.36(200) may be a toggle switch 
residue in CB1 [30].  Additionally, the aromatic residues often conserved at residue positions 
6.52 and 5.47 have been suggested to be part of a rotameric toggle switch. The crystal structures 
of the β2-AR[31], A2-AR[9], D3-R[10], and CXCR4-R[11] suggest that in an inactive state the 
aromatic residue at locant 6.52 adopts a χ1 = g+ conformation, which directly blocks the rotamer 
change of W6.48. Mutation studies of the β2-AR [26] and the D2 dopamine receptor [32] support 
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that 6.52 is associated with the rotameric change of 6.48, suggesting that these residues may 
change rotameric states in tandem. Additionally, the conserved aromatic residue at locant 5.47 is 
suggested to stabilize the activated, 6.48 χ1 = trans rotamer in the class A GPCRs GPR119, 
GPR39, β2-AR, and ghrelin [28].  
The focus of the thesis research reported here is the class A GPCR, GPR35. GPR35 is a 
recently identified [33] and de-orphanized [34] GPCR. GPR35 has been suggested to be involved 
in metabolism [35], heart failure [36], inflammation [37], asthma [38], a mental retardation 
syndrome associated with the deletion on 2q37.3 [39], type II diabetes [40], as well as gastric 
cancer formation [41]- making GPR35 a potential target for the treatment of multiple diseases. 
Due to the extremely broad range of GPR35 physiological involvement, understanding its 
mechanisms of action and ligand interactions may result in a wide diversity of therapeutic 
applications, including the development of potential pharmaceutics.  
Human GPR35 (hGPR35) has been shown to exhibit prominent expression in immune 
and gastrointestinal tissues [34], with additional expression in pancreatic islets, skeletal muscle, 
lung tissue [42], and the dorsal root ganglion [43]. The rat GPR35 (rGPR35) analog, which has 
72% sequence identity with hGPR35 [43], has been shown to have expression in similar tissues as 
with hGPR35, but with the addition of high to moderate expression levels in uterine and neuronal 
tissues respectively [43]. There have been two isoforms of hGPR35 identified, GPR35a and 
GPR35b. The GPR35b splice variant was first identified from a human gastric cancer cDNA 
library [41] and contains an additional 31 amino acids at the N-terminus. HEK293 cells 
transfected with both hGPR35 and chimeric G-protein α-subunits have suggested that hGPR35 
couples to  G i/o proteins [43]. This was supported by the inhibition of GPR35 agonist dependent 
[Ca+2] attenuation by Bordetella pertussis toxin in hGPR35-transfected rat sympathetic neurons 
expressing only native G-proteins [44]. This was recently contrasted in 2011 by data published by 
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Jenkin et al., which suggest that the pertussis toxin-sensitive G proteins were only able to elicit a 
very modest signal in a [35S]-GTPγS assay following GPR35 activation in a similar HEK293 
system [45]. Further experimentation, involving both the chimera and native Gα13 subunits in a 
HEK293 cell system, suggest that the Gα13 subunit couples to the active GPR35 complex [45].  
Preliminary unpublished data from a collaborator of the Reggio lab, Mary E. Abood, had 
originally suggested that GPR35 might be a candidate cannabinoid receptor. GPR55, which has 
recently been hypothesized and experimentally suggested as a novel cannabinoid receptor, shares 
27% sequence identity with GPR35 and is mapped to the same chromosome, 2q37. Preliminary 
experiments suggested that human GPR35-transfected HEK293 cells demonstrated cannabinoid-
stimulated GTPγS binding with two non-classical cannabinoids, CP55940 and Win55212-2- with 
CP55940 yielding a high potency (EC50 ≈ 14nM). Unfortunately these results were not 
reproducible and have been contrasted in 2010 by those of Sonoda et al [46], whose data suggests 
that non-classical cannabinoids, CP55940 and the aminoalkylindole,WIN55212-2, are not able to 
elicit an increase in free intracellular [Ca2+] in hGPR35-transfected HEK293 with ligand 
concentrations as high as 10 μM. The cannabinoid receptor ligand ∆9THC, the principal 
psychoactive component of marijuana, did produce a detectable increase in intracellular [Ca2+], 
but at concentrations of 5 and 10μM. These data suggest that GPR35 may be in a class separate 
from the cannabinoid receptors.  
The first possible endogenous ligand of GPR35 to be identified, kynurenic acid [37], is 
one of the major metabolites of the kynurenine pathway; a pathway which is the main route of 
tryptophan catabolism and has been associated with important physiological roles in the brain. 
While kynurenic acid (Figure 3) has been shown to be a moderate to a low potency agonist in 
hGPR35, with an EC50 of 36 - 39 μM [34], it has been shown that hGPR35 elicits firm adhesion 
of leukocytes in vitro at kynurenic acid concentrations as low as 300 nM [37]. The baseline 
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Another recently discovered moderately potent hGPR35 and rGPR35 agonist, with 
respective EC50s  of 4.4-12 μM [58-59] and 16 μM, is the chloride channel blocker 5-nitro-2-(3-
phenylpropylamino)benzoic acid (NPPB) [58]. A previous pharmacological study looking at 
NPPB’s (Figure 6) effect on the constriction of rat small pulmonary arteries, has shown activity 
suggested to be based on the inhibition of N-type calcium channels independent of the blocking 
of chloride channels [61]. Activation of GPR35 in transfected hGPR35 cells has been shown to 
activate native Gi/o, which in rat sympathetic neurons has been suggested to lead to [Ca
2+] 
modulation through the inhibition of N-type calcium channels. These data suggest that GPR35 
may naturally be involved in this mechanism. While these data may suggest another potential 
mechanism of GPR35, NPPB is limited as a tool to study the mechanisms of GPR35 for similar 
reasons as Zaprinast- promiscuity and moderate potency.  
Figure 5. The Structure of Zaprinast
Figure 6. The structure of 5-nitro-2-(3-
phenylpropylamino)benzoic acid (NPPB) 
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Two additional ligands that have been found to be GPR35 agonists are the asthma drugs 
cromolyn sodium (Intal) [38, 57] and nedocromil sodium (Tilade) [38], each with an EC50 
measured to be similar to Zaprinast. Cromoglicic acid (Figure 7B) is suggested to have a similar 
potency in hGPR35 and rGPR35 [38, 57], while nedocromil sodium (Figure 7A) is suggested to 
be more potent in rGPR35 as compared to the human orthologue [38]. Both of these drugs are 
thought to act as mast cells stabilizers, preventing the release of inflammatory stimulating 
chemicals such as histamine, though the target nor the exact mechanism of action of either of 
these drugs is known definitely [38]. These data suggest that GPR35 may be involved in the 
disease of asthma, but due to the ambiguity of the target of these drugs, the degree of GPR35 
selectivity is uncertain. For this reason and due to their moderate potency for GPR35, these drugs 
are not ideal candidates to help understand the mechanisms of GPR35. 
A potent hGPR35 agonist, pamoic acid (Figure 8), originally identified by a collaborator 
with the Reggio lab, Mary Abood [59], is novel compared to the other currently known ligands of 
GPR35. Pamoic acid is more potent than any other currently known exogenous ligand for GPR35, 
with calculated EC50 values of between 51 - 79 nM [57, 59] and no additional currently known 
target receptors. Currently, the Food and Drug Administration has pamoic acid classified as an 
Figure 7. The structures of (A) Nedocromil (Tilade) 
and (B) Cromoglicic acid (Intal).  
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Recent mutation data in both the human and rat GPR35 receptors have suggested both 
binding location and, in conjunction with an accurate model, possible direct interaction residues 
for the ligands zaprinast and pamoic acid. Mutation data of hGPR35 from the Reggio lab 
collaborator, Mary Abood, has suggested several residues that may be important in ligand binding 
and or activation [63]. The residues R6.58(240), R4.60(151), R3.36(100), and K7.40(263) (Figure 
10) were all mutated separately to alanine and stably expressed in U2OS cells. The potency of the 
agonists zaprinast and pamoic acid were assessed for each mutant. Mutant R3.36A(100) was not 
recruited to the cell surface, so it is speculated that this mutation may have led to the misfolding 
of the protein. Data published in 2011 by Jenkins et al suggests that in stably transfected 
HEK293T cells, both the human and rat GPR35 R3.36 (human/rat, 100/97) mutant receptors are 
recruited to the cell surface, but with a trend in the reduction of surface expression as compared to 
the wild-type receptor, with a significant reduction in the rat GPR35 mutant [45]. Though these 
mutants showed expression on the cell surface, neither receptor was able to be activated by the 
agonists pamoic or kynurenic acid. Considered together, both the trend in the reduction of the 
receptor cell surface expression and the inability to be activated by wild-type agonists suggest 
that this mutation may indeed cause protein misfolding. The R4.60A(151) mutant expressed on 
the cell surface, but was unable to be activated by either agonist tested, suggesting that this 
residue may be involved in ligand binding, protein folding, and/or protein stabilization. The       
Figure 9. The structure of the compound MLS- 0370945. 
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R6.58A(240) mutant showed a statistically significant increase in the potency of zaprinast, while 
not affecting pamoic acid. The K7.40A(263) mutant showed no statistically significant difference 
in potency for either zaprinast or pamoic acid, suggesting that K7.40(263) is not a direct 
interaction residue for these ligands. Since many of the ligands for GPR35 are anions and 
K7.40(263) is the only positively charged residue in the TMH1-2-7 region of GPR35, a lack of 
change in potency in the K7.40A(263) mutant suggests that the binding pocket of GPR35 lies 
rather in the TMH3-4-6 interface, where there are potentially four arginine residues available for 
direct ligand interaction- residues R3.36(100), R4.60(151), R6.58(240) and R(164) located on the 
EC2 loop. The recent data published by Jenkins et al suggest that Y3.32(human/rat, 96/93) may 
be a direct interaction site for zaprinast [45]. The Y3.32L(93) mutation resulted in an 
approximately 60-fold increase in the EC50 of zaprinast for rGPR35, suggesting that this may be a 
direct interaction site. In the hGPR35 Y3.32L(96) mutant receptor, the ability to be activated by 
Figure 10. Locations of the mutated residues in hGPR35 by experiment 
collaborator, Mary Abood. 
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zaprinast was undetectable, though this may be due to the potency difference between rat (16-67 
nM) and human GPR35 (0.84 – 2.6 μM). If this mutation caused a similar 60-fold increase in the 
much higher EC50 of zaprinast for hGPR35, than this may increase the concentration of zaprinast 
needed to elicit a response beyond a reasonable level. 
To first assess the ligand binding data and make well-informed mutation 
recommendations for GPR35, an initial in silico homology model based on a rhodopsin template 
was constructed in the Reggio lab. GPR35 and rhodopsin share most of the highly conserved 
residues and motifs found in class “A” GPCRs, but have two major sequence variations with the 
addition and the lack of a proline in TMH1 and TMH2 respectively.  The GPR35 model 
developed here is based on two different crystal structure templates; the A2-AR crystal structure 
[9] for TMH7 and Hx8 and the β2-AR crystal structure for the remaining TMHs [7]. While the 
β2-AR shares a relatively low sequence identity of 14% with GPR35, the two receptors share 
multiple conserved residues across all TMHs including the highly conserved residues N1.50,  
D2.50, W4.50, P5.50, P6.50 and the conserved E/DRY motif on TMH3. The GPR35 and the β2-
AR sequences also share a conserved cysteine at position 3.25, which in the β2-AR crystal 
structure is involved in a disulfide bridge to a cysteine on the EC2 loop. GPR35 also has a 
cysteine in the EC2 loop and is presumed here to be involved in a disulfide bridge with 
C3.25(89). GPR35 and the β2-AR, but not the A2-AR receptor, also shares the conserved residue 
F5.47, which has been suggested to stabilize the active bundle [28]. The A2-AR receptor was 
used as a template in lieu of the β2-AR for TMH7 and Hx8 because GPR35 and the A2A receptor  
both have a two residue elbow region connecting TMH7 and Hx8, while the β2-AR only has one.  
While GPR35 shares multiple conserved residues and motifs with other GPCRs that have 
available crystal structures, there are major sequence variations in several TMHs of GPR35 that 
do not have a crystal structure counterpart. The GPR35 receptor sequence differs from the 
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available GPCR crystal structures mainly in the positions of common proline residues in TMH2, 
4, 5, and 7 (Table 1). The lack of the proline in the highly conserved NPXXY motif of TMH7 in 
the GPR35 sequence, which is DAICY at the analogous residue positions, is predicted to have the 
largest structural variation from the other known GPCR structures.  While the addition, 
subtraction, and shift of prolines in the GPR35 sequence are likely to cause variant helical 
distortions as compared to other GPCRs structures, there are also multiple non-conserved 
threonines, glycines, and serines in TMH1, 2, 4, 5, and 6 that have the potential to exert subtle,  
but potentially important helical deformations. Residues serine and threonine (i) in a χ1 = g- 
conformation may result in a hydrogen bond between the side chain hydrogen bond donor of the 
(i) residue and carbonyl oxygen of the residue located at approximately one turn towards the N-
terminius (position (i -3) or (i-4)), resulting in the induction and stabilization of a 3-4° bending in 
the helix [64] 
 
Table 1. GPR35 TMH 2, 4, 5, and 7 sequence position differences of common proline residues. 
 
 
 
 
 
.  
Helix Number Change in Proline as compared with GPCRs with available Crystal Structures 
TMH2 P2.58 in GPR35 instead of 2.59 
TMH4 R4.60 in GPR35 instead of P4.60 
TMH5 presence of non-conserved P5.43 in GPR35 
TMH7 Lack of NPXXY motif ; this is replaced with DAICY in GPR35 
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CHAPTER II 
 
HYPOTHESES & METHODS 
 
 
Hypotheses 
 
The ultimate focus of this project was the development of human and rat GPR35 models that are 
consistent with specific known pharmacology of this important receptor. To this end, three 
separate homology models, a human GPR35 R, a human GPR35R*, and rat GPR35 R* model, 
were constructed and refined. Conformational analyses were performed on the agonists pamoic 
acid and zaprinast and the antagonist MLS-0370945 to calculate plausible conformations 
available at physiological conditions. Docking studies with each receptor were performed to test 
the following hypotheses: 1) the increase of the potency of zaprinast in the hGPR35 R6.58A 
mutant receptor is due to the excision of the bulk of the R6.58 arginine residue, which allows for 
additional interactions with the ligand, 2) the increase and decrease of the potency of zaprinast 
and pamoic acid respectively at rGPR35 vs. hGPR35 is primarily due to the conformational 
differences in TMH5 caused by the lack of the non-conserved proline on P5.43 in rGPR35, and 
3) the statistically equivalent potencies of pamoic acid for the wild-type and R6.58A 
mutant hGPR35 receptors is due to a similar binding affinity of pamoic acid in each of 
these receptors. 
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Methods 
Modeling of GPR35 using GPCR crystallization data  
During the initial development of the model presented here, only a few GPCRs had been 
crystallized, including Rhodopsin (Rho) [2-4], Opsin [6] the β2-adrenergic receptor (β2-AR) [7, 
31, 65], the β1-adrenergic receptor (β1-AR) [66], and the A2-adenosine (A2-AR) receptor [9]. 
The model of the activated form of GPR35 is based on the 2.4 Ǻ and 2.6 Å resolution crystal 
structures of the A2-AR [9] and β2-AR [7], respectively. The initial, canonical comparison of 
GPR35 with other class “A” GPCRs was based on a sequence comparison. The GPR35 sequence 
was aligned with the sequences of Rho, β2-AR, A2-AR, and the CB1 and CB2 receptors, using 
highly conserved residues as templates as done previously for the CB1 [67]  and CB2 [68] 
receptors. GPR35 contains several of the highly conserved residues patterns in TMHs 1, 2, 3, 4, 5 
(N1.50, D2.50, (E) DRY motif in TMH3, C3.25, W4.50, and P5.50) of other crystallized GPCRs, 
with notable sequence variations including: 1) a conservative substitution (CFLP) for the TMH6 
CWXP motif, 2) a non-conservative substitution (DAICY) for the TMH7 NPXXY motif, and 3) a 
non-conservative proline addition in TMH5 (P5.43). Additionally, the GPR35 extracellular (EC) 
EC-1 loop is shorter than most (2 amino acids (aa) vs. 6 in β2-AR and Rho) and the GPR35 EC-2 
loop is longer than most  (GPR35 11 aa vs. 5 aa in β2-AR, 6 aa in Rho and CB1/CB2, 7 aa in A2-
AR).         
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Conformational Memories (CM) 
 
 
In order to explore the consequences of a change in the location of a helix deforming 
residue from the template structure, the Conformational Memories technique was employed. The 
CM technique uses multiple Monte Carlo/simulated annealing random walks employing the 
CHARMM all-atom force field [69] in a distance dependent dielectric at 310 K. This method 
allows for an exploration of the available conformational space of each TMH and is able to 
converge in a reasonable number of steps. To ensure a reasonable computational time, the Monte 
Carlo method is preferred over a systematic approach due to the flexible nature of these large 
molecules. The inclusive rotation of the large number of “degrees of freedom” is approximated 
through numerous steps in which two dihedrals and one bond angle are rotated at random. 
Simulated annealing allows for the exploration of all allowed amino acid rotamers and backbone 
dihedrals by energizing the system to overcome potential energy barriers. The acceptance or 
rejection of each conformer is based on the Metropolis criterion [70], so the energies of the 
accepted structures are representative of a Boltzmann energy distribution at the measured 
temperature. This ensures that the final accepted conformers are reasonable at physiological 
temperatures. The CM calculations were performed in two phases: the exploratory and the biased 
phase. In the exploratory phase, the simulated-annealing process has an initially high starting 
temperature of 3000 K to ensure that the range of each allowed angle is capable of being 
explored. The accepted conformers from the exploratory phase are stored as “memories” and are 
used to restrict the conformational search performed in the biased phase.  A more detailed 
description of the CM method is provided below: 
In the exploratory phase, the range that each angle is capable of exploring is determined by 
starting at a temperature of 3000 K and decreasing to 310 K in 18 steps. For each temperature 
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step, 50,000 Monte Carlo moves are performed in which two dihedrals and one bond angle are 
varied. Accepted conformers are stored as “memories” and are used to restrict the bond angles 
and dihedrals that are explored in the biased phase. The “memories” are a representation of a 
probable distribution of different angles and dihedrals of each TMH as a function of temperature.  
The biased phase begins at a temperature of 750 K and decreases to 310 K in 7 steps. As 
with the exploratory phase, for each temperate step 50,000 Monte Carlo moves were performed 
and the conformers were accepted or rejected based on the Metropolis criterion. In the biased 
phase only those dihedral and angle ranges that were suggested to be accessible at 310 K in the 
exploratory phase were explored. In each CM calculation, a total of 105 TMH conformers were 
generated.  
The sampling ranges for backbone dihedrals Φ (phi), Ψ (psi), ω (omega) were standard 
values of ±10°, ±10°, ±20°, respectively, and the side chain dihedrals were allowed to vary 
±180°. The initial dihedral angles used in CM were transformed from the starting angle of the 
pre-generated structure to an integer in the range of -180° to 180°; which was restricted to five 
degree increments (i.e. -5, 0, 5). An example of this is a pre-generated starting structure dihedral 
angle of -13.4° would be transformed to -15°. The bin ranges were 5°, which gave a minimum 
range of motion of 10° for explored dihedrals. Bond angle variation ranges were defined as either 
±8° for default bond angles or ±15° for sidechain bond angles involving polar hydrogens (i.e. C-
O-H: Ser, Thr, Tyr) or the flexible C-S-C bond angle in methionine as described by Whitnell et al 
in 2008 [71]. To avoid the sampling of high energy bond angles, various restrictions were 
implemented as described by Whitnell et al [71]. The bond angles present in aromatic rings and 
those involving non-polar hydrogens in methylene and methyl groups were not sampled.  Based 
on the examination of all-atom and united-atom topology files [71],  a pre-biased “memory” was 
applied to all bond angles restricting the ranges to 90° – 144° with 1.5° bin ranges.   
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Analysis of Conformational Memories Transmembrane Helicies 
 
 
Analyses of helix bends were performed by the program ProKink [72], which is 
embedded in the Simulaid Conversion program [73].  This method quantifies three attributes of 
the helix's coordinates as compared to a “hinge” residue; the wobble angle, the face-shift, and the 
bend angle (Figure 11). As the first point of reference, the α-carbon of the hinge residue is 
translated to the Cartesian origin and the “pre-hinge” central helical axis (HAx) is aligned parallel 
with the positive x-axis. The HAx is calculated by the Kahn method [74]. The bend angle (Figure 
11B) is measured by first aligning the “post-hinge” HAx axis to the x,y plane. The angle that the 
“post-hinge” HAx axis makes with the “pre-hinge” HAx axis is defined as the bend angle.  At 0°, 
the hinge is straight and 180° the angle is bent (bent angle). The measurement of the wobble 
angle (Figure 11A) requires the parallel alignment of the “pre-hinge” HAx to the x-axis and the 
alignment of the α-carbon of the hinge residue with the y-axis. The wobble angle (-180°,-180°) is 
the angle that the “pro-hinge” HAx makes with the y ,z-plane, with 0° representing the “pro-
hinge” HAx  moving towards the α-carbon of the hinge residue. The final attribute, the face-shift 
(Figure 11C, D, and E), is calculated by aligning the “post-hinge” HAx with the negative x-axis.  
The α-carbon of the hinge residue is aligned with the y-axis and angle between this and the 
projection of the average of the vectors of the ɑ-carbons of the (i – 3) and (i – 4) represents the 
face-shift (0°-180°). A value close to 0° is an ideal helix while a positive or negative value 
represents an under or over wound helix.  
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Figure 11. Representation of the three quantifiable attributes of a proline-kink as defined in the 
program PROKINK. The attributes are defines as A) Wobble Angle, B) Bend Angle, C) Face-shift 
(over-wound), D) Face-shift ((ideal), E) Face-shift (under-wound). 
 
Implementation of the CM Technique to Calculate the TMH Region of the GPR35 Model 
 
For TMH 1, 2, 4, 5, 6, and 7, a series of possible, sequence-dictated conformations that 
deviated from the β2-AR or A2-AR template were calculated using the CM simulated annealing 
technique [71, 75]. In this technique, nearly all dihedrals and bond angles are defined as variable, 
with various restrictions.  The dihedral ranges allowed were based on the sequence of the TMH 
being explored. If the sequence contained a known helix deforming residue such as proline or 
glycine, a larger variation range of up to ±50° on the Φ and Ψ was implemented to permit 
increased flexibility. The proline residue often creates the largest helical distortion. This helical 
distortion, often referred to as a proline kink, is suggested to affect the Φ and Ψ dihedral angles of 
the proline (i) to the fourth residue preceding it (i – 4). The justifications for the ranges that were 
explored for TMH 1, 2, 4, 5, 6, and 7 are described below. 
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TMH 1, 2, 4, and 7 
 
Due to either the lack of a proline or the a lack of a homologous proline locant found in any 
available crystal structure, TMH1, 2, 4 and 7 used the ideal phi/psi angles of -63°/-41.6° [12] as 
starting structures.  
 
TMH7:  TMH7 in GPR35 lacks the conserved P7.50 in the NPXXY motif and instead 
has the non-conservative substitution of DAXXY. The TMH2 of Rhodopsin, which lacks the 
conserved proline, contains a sequence of Gly-Gly which acts as a proline analog in terms of its 
increased flexibility. The Gly-Gly motif in the TMH2 of Rhodopsin creates a helix distortion 
which emulates the shape of the proline containing TMH2 of the β2-AR and the A2-AR. To 
determine if the GPR35 TMH7 sequence may dictate a proline-like distortive quality analogous 
to the Gly-Gly motif of the TMH2 of rhodopsin, a sequence a flexible region (Φ/Ψ ± 50°) was 
introduced in the virtual i to (i -4) region (C7.46(269) - A7.50(273)) of TMH7. TMH7 also 
contains two possible helix distorting residues, S7.39(262) and S7.42(265). These residues were 
both held in χ1 = g- independently and concurrently to access their ability to distort the helix.  
 
TMH2:  GPR35 has a proline that is shifted by one residue extracellularly as compared to 
the β2AR sequence: P2.59 in the β2AR and P2.58 in GPR35. A flexible region (Φ/Ψ ± 50°) was 
implemented into the P2.58 (i) to L2.54 (i – 4) region to mimic the flexibility imposed by the 
proline.  
 
TMH4:  GPR35 does not have the conserved proline located at the extracellular end of 
the β2AR TMH4. To determine if a sequence dictated conformation might emulate the distortion 
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typically associated with this conserved proline, the helix deforming potential of the G4.55(146) 
–R4.60(151) region was analyzed. Two independent conformational searches were performed; 
the first search explored what effect the increased flexibility of the backbone (Φ/Ψ of ± 50°) in 
the region of G4.55(164) – R4.60(151) would have on the shape of TMH4 and the second 
conformational search used the same protocol as the first, but with the addition of S4.56 held in 
g-.  
TMH1: Due to the straightening of the adjacent TMH7, the conformation of TMH1 was 
explored. TMH1 has three non-consecutive glycines located at positions 1.34, 1.39, and 1.46. 
Since all of the glycines were non-consecutive, three independent calculations were performed. In 
each calculation a single glycine was given increased flexibility of the backbone (Φ/Ψ of ± 50°) 
and assessed independently.  
 
TMH 5 and 6 
 
In TMH5 and 6, the proline locations in GPR35 are inclusively conserved in all currently 
available GPCR crystal structure sequences. The dihedral angles associated with the proline kink 
in these helices were examined from Rhodopsin [2], A2-AR [9], and  β2-AR[7] and were used to 
constrain the range of the possible sampling of dihedral angles. The exploratory ranges of the i – 
(i-4) backbone dihedral angles of TMH5 and 6 were restricted to those ranges found in their 
respective crystal structure TMH (Table 2 and Table 3). These constraints allowed for CM to 
generate conformations of helices with structural similarities to the available crystal structures. 
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TMH5:  TMH5 has two proline residues; the conserved proline at position 5.50 and an 
additional proline at 5.43. The additional proline at 5.43 was assumed to induce a local 
conformational change that is independent of P5.50(183).  The flexibly of the proline kink of the 
conserved proline (G5.45(178) to P5.50(183)) was restricted to empirically based backbone 
dihedral ranges and the proline kink of non-conserved proline (S5.39(172) to P5.43(176)) was 
given the full increased flexibility of the backbone (Φ/Ψ of ± 50°). 
 
TMH6: TMH6 in GPR35 lacks the highly conserved CWXP motif and has a conservative 
substitution of CFXP. The highly conserved proline in TMH6, P6.50(232), is expected to provide 
a large amount of flexibility of GPR35’s TMH6. GPR35 contains only one other potential helix 
deforming residue, G6.54(236), which was given an increased backbone flexibility of ± 50° for 
the Φ and Ψ dihedral angle in all calculations. The importance of exploring the possible 
conformational space of TMH6 lies in the structural changes associated with the transition from 
an inactive (R) to an active (R*) GPCR bundle.  In β2-AR and rhodopsin, the most dramatic 
structural change associated with activation is the general rotation and straightening of TMH6 
about the highly conserved CWXP hinge region [13-20]. Two independent conformational 
searches were performed with an identical, ideal helix starting structure to be representative of 
either an R or R* state. The inactive TMH6 is expected to both have a similar structure to the 
antagonist bound GPCR crystal structures and to have the suggested toggle switch residue 
F6.48(230) in a χ1 = g+ rotameric state. To achieve a set of conformers that met these criteria the 
flexibly of the i – (i-4) region (V6.46 to P6.50) of TMH6 was restricted to the empirically based 
backbone dihedral ranges (Table 3) and the residue F6.48(230) was held in a χ1 = g+ rotameric 
state. To calculate the possible TMH6 conformations for the R* model the standard ± 50° for the 
Φ and Ψ dihedral angles of the i – (i-4) region were explored.  
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Construction of the TMH region of GPR35 
 
The conformers generated by the CM calculations were used to construct the TMH 
bundle region of the receptor. The receptor was assembled by aligning the intracellular region of 
TMHs 1, 2, 4, 5 or TMH7 with their respective crystal structure templates of the β2-AR or the 
A2-AR. For all superimpositions, the C, Cα, and backbone N atoms of the TMH conformers 
calculated by CM were superimposed with the corresponding atoms of the analogous residues on 
the crystal structure template. The region chosen for the backbone alignment of each TMH was 
variable. TMH1, which lacks a proline, was aligned with the backbone of the residues that 
correspond with the GPR35 sequence G1.46(34) - F1.57(45).  This alignment was chosen to 
ensure that the highly conserved N1.50 was aligned properly, but the potential conformational 
impact from the highly flexible glycines at residue position G1.34(22), G1.30(18), and G1.46(34) 
would be explored.  For TMHs 2, 4, 5, and 6, which contain a proline in the crystal structure 
template, the region chosen for superimposition was based on avoiding the region distorted by the 
proline. The regions chosen for alignment for TMH2, 4, and 5 were as follows: TMH2: E2.38(54) 
- L2.57(73), TMH4: R4.40(131) - W4.50(141), and TMH5: P5.50(183) - A5.66(199). For TMH6, 
the residues chosen for superimposition varied between the active and inactive state. For the 
inactive bundle, the CM calculated helices were superimposed intracellularly with the β2-AR 
crystal template residues that correspond with the GPR35 sequence T6.30(212) - V6.46(228). For 
the active bundle, the CM calculated helices were superimposed extracellularly with the 
backbone of the residues P6.50(232) - V6.61(243) of the final GPR35 inactive (R) bundle. The 
TMH6 of the GPR35 R bundle was chosen in lieu of the β2-AR due to the biophysical data for 
rhodopsin, that suggests that the extracellular region of more stationary TMH5 [18] and the 
dynamic TMH6 are in the same relative orientation in either the R and R* state [76]. As discussed 
earlier, the template used for the alignment of TMH7 was the A2-AR receptor in lieu of the β2-
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AR, due to the more similar elbow length. TMH7, which has the non-conservative substitution 
DAICY for the highly conserved NPXXY motif, was aligned with the proline kink region due to 
the energetically unfavorable large gap that occurred between the extracellular tops of TMH7 and 
TMH6 when the superimposition avoided the proline distortion.  The CM calculated conformers 
were superimposed with the backbone of the residues in the 7.45 to 7.57 region of the A2-AR 
template.  
 The TMH3 developed as the starting structure for the GPR35 homology model was based 
considerably on the β2-AR template. The TMH3 of the β2-AR crystal structure, N3.22(103) to 
S3.56(137), was mutated to the GPR35 sequence and, after rotameric changes of residues to 
eliminate overlap, was energy minimized for 500 iterations employing the OPLS2005 all atom 
force field, extended cutoff (nonbonded: 8.0Å, electrostatic: 20.0Å, hydrogen bonding: 4.0Å), 
and a distance dependent dielectric in Macromodel 9.1 (Schrodinger Inc., Portand, OR). A 
harmonic constraint of 1000 kcal/mol was implemented on the backbone dihedrals to maintain 
the backbone conformation of the crystal structure.  
The CM TMH conformers for each explored helix were aligned to their crystal structure 
template, as described above, and the iterative process of choosing the final transmembrane 
helices was based on two criteria: 1) eliminating the Van der Waals overlaps with other helices 
within the bundle and 2) creating an overall topography conducive for the inclusion of the intra- 
and extracellular loops. Following the choice of the CM conformers, a modification on TMH7 
was made. Comparison of the TMH7 sequence of the A2-AR crystal structure and GPR35 
showed a homologous sequence motif (A2-AR: S7.42(277), H7.43(278), T7.44(279), 
N7.45(280), S7.46(281) vs. GPR35: S7.39(262), K7.40(263), L7.41(264), S7.42(265), 
D7.43(266)) which in the A2-AR created a helical deformation independent of the proline kink 
initiated by P7.50.  To emulate this motif the backbone dihedrals (Φ and Ψ) of the GPR35 TMH7 
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were changed to match the corresponding dihedrals of the A2-AR crystal structure. Matching the 
motif found in the A2-AR crystal structure shifted the position of the charged residues 
K7.40(263) and D7.43(266) (which initially faced towards the lipid)  into the likely hydrophilic 
TMH1-2-7 cavity.   This helical manipulation also reduced the unfavorable gap between the 
intracellular tops of TMH6 and 7. Additionally, the crystal structure of the A2-AR helix 8 and the 
two residues that precede it were mutated to the GPR35 sequence and subsequently attached to 
the chosen CM TMH7.  
Several waters were added to the bundle based on the positions and abundance of the 
crystallographic waters found in the A2-AR [9], β2-AR [31], and rhodopsin [2] crystal structures. 
An average of three water molecules was found in proximity to the highly conserved N1.50, 
D2.50, and N7.49 interface. These waters were involved in a hydrogen bond network with each 
other and with D2.50 and either N7.49 or N1.50, depending on the crystal structure. Three waters 
were placed in this interface of the GPR35 model, with hydrogen bonds formed with each other 
and the residues at loci 1.50, 2.50, and 7.49. There was also a single water molecule found near 
the highly conserved R3.50 in the aforementioned crystal structures. To emulate these, a single 
water molecule was placed in the GPR35 model near R3.50(114). 
For the inactive (R) bundle, several highly conserved residue sidechain dihedrals were 
restrained to crystal structure ranges (Table 4). To emulate the highly conserved salt bridge found 
between the residues R3.50 and E/D6.30 in multiple GPCRs, a harmonic restraint of 12.5 kj/mol 
with distance constraints of 2.8 ± 0.4 Å and 7.0 ± 1.0 Å on the hydrogen bond donor/acceptor 
heteroatoms and Cα respectively of the residues R3.50(114) and T6.30(212) was implemented. 
Additionally for the R bundle, several residue interaction pairs/motifs, supplemental to the 
interaction between R3.50 and T6.30, were required to be possible with low energy sidechain 
rotamers. These interaction pairs/motifs include: 1) the mimicking of the aromatic stacking of 
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residues 5.47, 5.48, and 6.52 (GPR35:F5.47(180), Y5.48(181), H6.52(234) vs. D3/β2-AR F5.74, 
Y5.48, F6.52) found in the crystal structures of the β2-AR and human dopamine D3 receptor 
(D3-DR) [10]; 2) the emulation of an aromatic stack between the highly conserved residues 
Y7.53(276) and F7.60(283), the first residue on helix 8, found in the rhodopsin crystal structure 
and is suggested by mutation studies in the 5HT2C receptor [77]; and, 3) the imitation of the 
highly conserved D3.49(113) and R3.50(114) arginine cage motif of the E/DRY sequence, which 
is present in all current inactive GPCR crystal structures.  Additionally, the χ1 of F6.48 and H6.52 
were required to adopt a χ1 = g+ conformation, as suggested by GPCR crystal structures and 
other biophysical data.  
Table 4. Average values of side chain values of conserved residues based on the crystal structure 
values. ± 1 standard deviation (σ) based on the crystal structure values from β2-AR (2RH1): 2.40 Å, 
Rhodopsin (1GZM): 2.65 Å, A2-AR(2EML):2.60 Å 
 
 
The bundle was then pulled apart 3Å from TMH3 and then energy minimized for 3500 
iterations to pack the TMHs and relieve side chain clashes. This energy minimization utilized the 
OPLS2005 all-atom force field in Macromodel 9.1 (Schrodinger Inc., Portland, OR) employing a 
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distance dependent dielectric with extended cutoffs (nonbonded: 8.0 Å, electrostatic: 20.0 Å, and 
hydrogen bonding: 4.0 Å) and the Polak-Ribiere conjugate minimization scheme. Prior to energy 
minimization of the TMH region, all charged residues were neutralized except the residues 
D2.50(66), R3.50(114), K7.40(263), D7.43(266), and D7.49(272). A harmonic constraint of 1000 
kJ/mol was placed on the backbone (Φ, Ψ, and ω) to maintain helicity. Extra- and intracellular 
loops were generated via the program MODELLER 8.2 [78-80], described below. 
To create an active, R* model, multiple changes were implemented to transform the 
finalized R bundle. After excision of the EC2, EC3 and IC3 loops, the existing TMH6 was 
replaced with an extracellularly superimposed helix from the TMH6 CM output. In contrast to the 
restricted flexibility of TMH6 chosen for the R bundle, the TMH6 for the R* bundle was allowed 
full flexibility of the backbone (Φ/Ψ of ± 50°). To emulate β2-AR biophysical data, which 
suggests an increase in the water accessibility of C6.47 upon activation [15], TMH6 was rotated 
10° counterclockwise from an extracellular perspective. This rotation shifted C6.47 from a lipid 
environment to the water accessible pocket of the TMH6-7 interface. This rotation also moved 
the intracellular ends of TMH5 and 6 closer to each other, as suggested by both the opsin crystal 
structure [6, 17] and disulfide cross-linking studies of the M3 muscarinic acetylcholine receptor 
[23]. D3.49(113) was protonated to be representative of an active state, as suggested by pH-
dependent activation studies in β2-AR [81] and flash photolysis experiments on rhodopsin [82]. 
In 2007 Knierim et al. suggested that the protonation of E3.49(134) occurs subsequent to the 
movement of TMH6 in rhodopsin [83]. The χ1 rotamers of the toggle switch residues F6.48(230) 
and H6.52(234) were changed from g+ to trans along with the transition of the χ1 of Y7.53(276) 
from trans to g+ as suggested by the opsin crystal structures [6, 17]. Additionally, an offset 
parallel π-stack between F6.48(230) and F5.47(180) was created, as the interaction between these 
residues is suggested to stabilize the R* state [28]. With the remaining loops frozen, an energy 
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minimization with the same force field, cutoffs, and minimization scheme described earlier was 
performed for 500 iterations, with a distance-dependent dielectric. A harmonic constraint of 1000 
kJ/mol was placed on the backbone (Φ. Ψ, and ω) to maintain helicity. An additional harmonic 
constraint of 1000 kJ/mol was placed on the χ1 of F5.47(180) to maintain the experimentally 
suggested interaction between F5.47(180) and F6.48(230). The EC2, EC3 and IC3 loops were 
then generated via the program MODELLER 8.2 [79-80], described below. 
Modeling of the rat GPR35 R* Receptor 
 
The construction of the rat GPR35 R* bundle was performed in several steps: 1) TMHs 1, 
2, 3, 4, 6, and 7 of the final human GPR35 R* bundle were mutated to the rat sequence; 2) the 
EC2 and IC3 loops were removed; and 3) TMH5 from the β2-AR crystal structure was mutated to 
the rat sequence and substituted for the GPR35 human R* TMH5. With the loops and termini 
frozen, the TMH region was energy minimized for 500 iterations in a distance dependent 
dielectric, utilizing the same force field, cutoffs, and conjugate method described earlier, but with 
a harmonic constraint on the backbone (φ, ψ, and ω) of 1000 kJ/mol to maintain helicity. The 
EC2 loop was then modelled as described above, including the distance restraint to mimic the 
conserved disulfide bridge. The final loops were then energy minimized, as described above, until 
a gradient of 0.01 kcal/mol was achieved in a high, constant dielectric of 80.
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Generation of N- and C-terminus and EC/IC loops 
 
The program MODELLER 8.2 [78-80] was used to generate the geometries for the non-
transmembrane regions of the GPR35 model.  The N- and C-termini were defined as Met1-Pro16 
and Pro293-Ala309 respectively. The intra- and extracellular loops were defined as: IC1:Arg48-
Glu54, IC2: Pro121-Ser129, IC3: Ala199-Thr212, EC1: Asp82-Pro323, EC2: Leu153-Asn169, 
EC3: Val243-Arg255. During the loop generation the TMH regions were frozen, and in order to 
mitigate the bias that the position of the typical terminating residues would have on the loop 
topography, the defined loop length was adjusted. A range extension of ±1 residue was 
implemented into each loop to lessen this position bias of the terminal residues. Additionally, the 
length of the EC1 loop was extended due to the presence of the helix altering proline located at 
loci 3.32(87).  
MODELLER generates and optimizes a de novo loop/terminus using a pseudo energy 
function. This energy is a summation of multiple spatial restraints from the CHARMM force 
field, statistical preferences for backbone and side chain dihedral angles, and statistical 
preferences for non-bonding atom-atom interactions.  The method of conjugate gradients, in 
conjunction with simulated annealing and molecular dynamics techniques, is then used to 
optimize the energy function.  This program does not create loops/termini as if the receptor 
bundle was in an explicit bilayer, so each approximately 1000 structures that were generated by 
each MODELLER calculation were evaluated visually to determine the likelihood of their 
existence in this environment. If biophysical data was available, this was also used to govern the 
loop/terminus choice.  This is most represented in the EC2 loop where biophysical data suggests 
there is a disulfide bridge between the cysteine on the EC2 loop and C3.25. To create the 
disulfide bridge, MODELLER implements a distance, dihedral, and angle constraints on the Cα, 
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Cβ, and the sulfur of C(162) on the EC2 loop and C3.25(89) to force a disulfide bridge.  Other 
biophysical data that was used to direct the EC2 loop choice was based on substituted cysteine 
accessibility method (SCAM) studies of the dopamine D2 receptor[84], GPCR crystal structure 
data [2, 7, 9, 11, 31], circular dichroism studies of the Serotonin 5-HT4a [85], and NMR 
spectroscopic data from the β2-AR [86].  
 
Ligand Conformation Searches 
 
Complete conformational analyses were performed on the compounds zaprinast and 
pamoic acid using ab initio Hatree-Fock calculations at the MMFFs/HF 6-31+G* level in vacuum 
as encoded by Spartan ’08 (Wavefunction, Inc., 18401 Von Karman Ave., Suite 370, Irvine, CA 
92612).  For each conformational search, local energy minima were identified by the rotation of 
the subject dihedrals 360°, in 60° increments (6-fold search), followed by a MMFFs/AM1 energy 
minimization of each rotamer generated. The geometry and energy were then re-evaluated for 
each unique conformer calculated within 15 kcal/mol of the global conformer at the HF 6-31+G* 
level. For zaprinast, the energy minimum of each tautomeric form was assessed at the HF 6-
31+G*, HF 6-311+G**, DFT 6-31+G*, and DFT 6-311++G** levels of theory. Additionally, 
pamoic acid was also assessed at HF 6-31G* in a SM8 water solvation model as encoded by 
Spartan ’08  (Wavefunction, Inc.). The conformations of MLS-0370945 were initially assessed at 
the MMFFs/HF 6-31+G* theory in a vacuum environment. In vacuum the global low energy 
conformer adopted a folded conformation, which was proposed to be energetically less 
favourable in a water environment than an elongated conformation. Equilibrium geometries were 
therefore calculated using a Poisson-Boltzmann water solvation model (Dielectric 
Constant=80.37, Probe Radius=1.4Å).  These calculations were performed at the ab initio Hatree-
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Fock 6-31+G* level using Jaguar (version 9.0, Schrodinger, LLC, New York, NY) for three 
MLS-0370945 conformers: the global, the second low energy conformer, and a more elongated 
conformer. This calculation confirmed the more elongated MLS-0370945 conformer was 
significantly lower in energy in an aqueous environment.  
To calculate the conformational cost of docking, the rotatable dihedrals of the global 
minimum energy conformer were driven to the corresponding dihedrals of the final docked 
conformer and then were evaluated. The dihedrals were first driven to the final docked 
conformers utilizing the force field MMFFs as implemented by Spartan ’08 (Wavefunction, Inc., 
18401 Von Karman Ave., Suite 370, Irvine, CA 92612). With the rotatable dihedrals angles 
virtually fixed to the initial values, the equilibrium geometry and the energy of the resultant 
structure was then calculated at the HF 6-31+G* level and then compared to the global minimum 
energy calculated at the same level of theory in the same environment.  The final docked 
conformation of the MLS-0370945 compound was evaluated similarly in Jaguar (version 9.0, 
Schrodinger, LLC, New York, NY), with the inclusion of the Poisson-Boltzmann water solvation 
model.  
 
Docking of Ligands 
 
A low energy conformer of zaprinast and the global conformers of pamoic acid and 
MLS-0370945 were used as inputs for the receptor docking studies. The agonists zaprinast and 
pamoic acid were docked manually in the human wild-type and R6.58A mutant, and the rat 
GPR35 R* model, while the MLS-0370945 compound was docked solely in the human wild-type 
R bundle. Each receptor included the intra- and extracellular loops, as well as the N- and C-
termini.  Due to recent experimental data [45] Y3.32(human/rat, 96/93) was used as the primary 
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interaction site for zaprinast. Several arginine residues located near the binding pocket of 
zaprinast (R3.36(100), R4.60(151), R6.58(240) or R7.32(255)) were used as primary interactions 
for the di-anion pamoic acid. Although there is lack of independent experimental evidence 
regarding the docking site of pamoic acid alone, supplementary evidence [57] suggests that the 
binding pockets of pamoic acid and zaprinast share an overlapping binding site. The anionic 
MLS-0370945 compound, which antagonizes GPR35 activated by zaprinast (AID: 2079), is also 
suggested to share the same binding site at pamoic acid due to its analogous negative charge.     
Ligand/Receptor Minimization 
 
 
The ligand/receptor complexes were minimized using a Polak-Ribier conjugate gradient 
minimization and an OPLS2005 all atom force in Macromodel 9.1 (Schrodinger Inc., Portand, 
OR). An extended cutoff (nonbonded: 8.0Å, electrostatic: 20.0Å, hydrogen bonding: 4.0Å) was 
used in each stage of the calculation. The minimization was broken into three stages: 1) the 
extracellular loops EC2, 3 were minimized in a Generalized Born/Surface Area (GB/SA) 
continuum solvation model for water, while the TMHs and the ligand atoms were frozen, 2) the 
minimization of the ligand and the TMH region, while the loops and termini residues were 
frozen, and 3) subsequently an additional iteration of the first step.  
The first stage implemented a conjugate gradient minimization scheme as employed in 
Macromodel, with a GB/SA continuum solvation model for water and a force field defined 
dielectric. This stage consisted of either 1500 steps or until the 0.05 kJ/mol gradient was reached.   
In the second stage, the loops and termini were frozen during the conjugate gradient 
energy minimization. For the docking studies involving the ligand zaprinast and pamoic acid, the 
TMH region/ligand minimization, which used the force field and cutoffs described earlier, 
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consisted of two phases: 1) the TMH region was minimized for 20000 steps or until the bundle 
reached the 0.05 kJ/mol gradient in a distance-dependent dielectric of 3 (ε = 3) with the hydrogen 
bond and or cation-π restraints discussed below and 2) the repeat of protocol in the previous 
phase without the hydrogen bond and or cation-π restraints. The TMH region/ligand minimization 
for MLS-0370945 compound followed only the second phase of this protocol.   
The harmonic constraints placed on the ligand and or the receptor were variable and 
contingent on the receptor/ligand combination. In all of the docking studies, a harmonic 
constraint of 1000 kJ/mol were placed on select dihedrals of the ligands to maintain 
conformational similarity to the low energy conformer calculated at the HF 6-31+G* level of 
theory. The dihedral restraint for zaprinast maintained the internal hydrogen bond between its 
rings, the propoxyphenyl and azapurine-6-one functional groups. This restraint was implemented 
because the lowest energy structure which breaks this internal hydrogen bond was calculated at 
the HF-6-31+G* level of theory as 3.74 kcal/mol above the global minimum. The dihedral 
restraints for pamoic acid maintained the planarity of the carboxyl functional group with the 
naphthalene ring in the 3-hydroxy-2-naphthoic acid portion of pamoic acid. A similar restraint 
was placed on the dihedral of the MLS-0370945 compound to maintain planarity of the carboxyl 
functional group and the phenyl ring of the benzoic acid segment of this compound. In certain 
receptor/ligand combinations, a harmonic constraint of 1000 kJ/mol was also placed the arginines 
R4.60(151) or R7.32(255) to maintain rotamers that optimize the cation-π interactions not 
weighted for properly by the OPLS2005 force field. The R4.60(151) restraint was implemented in 
the pamoic acid docks in both the wild-type and R6.58A(240) human mutants receptor bundles, 
while the R7.32(255) restraint was employed in the docking of zaprinast in the R6.58A(240) 
mutant bundle only. A single set of restraints were implemented between the ligand and the 
human GPR35 receptors to preserve an experimentally suggested [45] hydrogen bond between 
38 
 
Y3.32(96) and zaprinast. Both an angle (150° ± 30°; 100 kJ/mol) and distance (2.8 ± 0.4 Å; 45 
kJ/mol) harmonic restraints were implemented to maintain this hydrogen bond during the 
minimization. Zaprinast docked in the rat GPR35 R* bundle had an analogous restraint between 
the ligand and Y3.32(93), with an additional restraint to maintain the hydrogen bond between the 
donor zaprinast and the acceptor S5.43(174), with duplicate constraints on the analogous atoms. 
The final stage was essentially an additional iteration of the first stage of the 
minimization. The TMH region and ligand were frozen and the extracellular loops, EC2 and EC3, 
were minimized in a GB/SA continuum solvation model for water with the same gradient, force 
field, and cutoffs described earlier. Contrary to stage 1, the loops were minimized for a maximum 
of 20000 steps to ensure that the 0.05 kJ/mol gradient was reached.  
 
Calculation of Ligand/Receptor interaction energy 
 
The energies of interaction (EOI) of the ligand/receptor complexes were calculated using 
the OPLS2005 all atom force field in Macromodel 9.1(Schrodinger Inc., Portand, OR) using the 
component interactions script. Each ligand/receptor interaction energies are the sums of the 
individual interaction energy between the ligand and each residue within a 6Å radius.  The 
energies were calculated with an extended cutoff (nonbonded: 8.0Å, electrostatic: 20.0Å, 
hydrogen bonding: 4.0Å) and a distance dependent dielectric of 3. The non-bonded interaction 
energies for each residue and the ligand were partitioned into van der Waals and electrostatic 
contributions. 
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CHAPTER III 
 
RESULTS 
 
 
Conformational Memories (CM) Output 
 
Because of the effect that changing one helix conformation has on other helices in the 
receptor, the helices are presented in the order in which they were fitted. 
 
TMH7 
The sequence of TMH7 in GPR35 does not have the conserved P7.50 found within the 
NPXXY motif, but instead has an A7.50(273). To determine if the sequence of GPR35 may 
emulate the flexibility of the proline kink caused by the highly conserved P7.50, an increased 
range of flexibility of ± 50° was given to the backbone in the analogous region of C7.46(269) - 
A7.50(273).  CM calculations suggest that the extracellular end of GPR35 TMH7 diverges from 
that of the template A2-AR structure (Figure 12). The bend angle of TMH7 shifts from 26.4° in 
A2-AR to 6.75° ± 3.20° in GPR35, as averaged by 105 CM structures. A7.50(273) was used as 
the “hinge residue” and i-7 and i+7 residues were the range of superimposition. The wobble angle 
of the CM TMH7 also differed from the A2-AR crystal structure, with values of -38.66° ± 97.27° 
for GPR35 and 176.3° for the A2-AR. These values suggest that the divergence of the 
extracellular end of TMH7is due to the lack of a proline at locant 7.50. Notable is that the 
superimposition of these CM helices on the A2-AR placed the Cβ atoms of the charged residue 
K7.40 facing toward lipid. As the positions of this charged residue is energetically unfavorable, 
calculations were performed which forced S7.39(262), S7.42(265), or both S7.39(262) and  
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TMH1 
 
GPR35’s lack of the highly conserved NPXXY motif found in the TMH7 of the crystal 
structure templates was assumed to cause a significantly straighter TMH7 than the templates, 
which may influence the conformation of the juxtaposed TMH1. Additionally, the proline 
position shift in TMH2 (β2-AR & A2-AR: P2.59, GPR35: P2.58(74)) is predicted to cause 
conformational consequences, which may be translated to the conformation of TMH1. TMH1 
was superimposed at its intracellular end on the backbones of the template residues at the 
positions 1.46 - 1.57 to ensure that the position of the highly conserved N1.50 was aligned 
properly. GPR35 has three non-consecutive glycines (G1.34(22), G1.40(28), and G1.46(34)) and 
to assess the potential impact of these flexible residues, three independent CM calculations were 
performed for each flexible region individually. In each Prokink calculation, the glycine 
(G1.34(22), G1.40(28), or G1.46(34)) that was assigned as the flexible region in the CM 
calculation was designated as the “hinge” residue. The largest divergence from the template was 
in the CM calculation where G1.34(22) was defined as the “hinge residue”.  This Prokink 
analysis, with i-5 and i+7 residues as the range of superimposition, calculates the average face 
shift, wobble, and bend angles as 12.75° ± 7.93°, -78.35° ± 89.77°, and 7.91° ± 3.96°, as averaged 
by 105 CM structures, vs. 16.8°, 7.9°, and 4.1° for β2AR. While these results suggest a large 
structural divergence from the template, visually it is apparent that the conformational divergence 
from the template is localized to the extracellular end of TMH1 (Figure 13-1).  With G1.46(34) 
identified as the “hinge residue”, with i-7 and i+7 as the range of superimposition, there was a 
deviation from β2-AR crystal structure in the wobble angle with the measured angle of -32.89° ± 
60.93° and -138.6 in GPR35 and the β2-AR crystal structure, respectively.  In the additional 
Prokink calculations, with G1.40(28) and G1.46(34) as “hinge residues”, the additional face shift, 
wobble, and bend angle averages are within one standard deviation of the β2-AR values. Each 
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CM calculated TMH1 are very similar (Figure 13) to each other and vary from the β2-AR 
template extracellularly, with a preference to lean towards either TMH7 or TMH2. 
 
Figure 13. Conformational Memories-calculated hGPR35 TMH1 superimposed on the β2-AR crystal 
structure. (PDB ID: 2RH1). Each set of 105 conformers (1 = G1.34 (22), 2 = G1.40 (28) or 3 = G1.46 
(34)) represents a different flexible region from two perspectives: an extracellular top-down view (a) 
and a side perspective (b) as seen from the lipid bi-layer interior. 
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TMH2 
 
GPR35 has a proline toward the extracellular end of the helix, but is shifted by one residue 
as compared to the β2-AR crystal structure (2.59 to 2.58). The TMH2 proline shift creates a face 
shift and wobble angle of  53.31° ± 26.90° and -90.53° ± 70.08°, as averaged by 210 CM 
conformers, compared to  99.6° and -5.0° for the β2-AR TMH2. P2.58(74) was used as the “hinge 
residue” with i-9 and i+10 residues as the range of superimposition. This shift allows for TMH2 
to move away from the bulk of the straight TMH7 (Figure 14).  
 
 
Figure 14. Conformational Memories-calculated hGPR35 TMH7 and TMH2 superimposed on the 
β2-AR crystal structure. Each sets of 105 CM-calculated helices of hGPR35 TMH7 and TMH2 on 
their respective  helices of the β2-AR crystal structure (PDB ID: 2RH1). 
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TMH5 
TMH5 has two Proline residues: P5.43(176) and the conserved P5.50(183). The range of 
flexibility of the backbone of the proline kink region (P5.50=i, flexibly range i to i-4) of the 
highly conserved P5.50 was limited to the crystal structure ranges of TMH5 (Table 2). The P5.43 
proline kink region (P5.43=i, flexibly range i to i-4) had a range of ±50° for the backbone 
dihedrals. The additional Proline at 5.43 induces a local conformational change (Figure 15). 
When the “hinge residue” is P5.43, with i-7 and i+6 residues as the range of superimposition, 
average face shift, wobble, and bend angles are calculated as 33.81° ± 17.88°, -23.08° ± 141.61°, 
and -27.36° ± 7.79° vs. 42.5°, 72.4°, and 25.7° for β2AR. When the “hinge residue” is 
P5.50(183), with i-10 and i+13 residues as the range of superimposition, the average wobble and 
bend angle is -86.96° ± 73.58° and 23.33° ± 6.85° for GPR35 vs. -76.3° and 21.0° for β2AR. This 
difference suggests that TMH5 leans away, as compared to β2AR, from TMH4 (Figure 15). 
 
 
Figure 15. Conformational Memories-calculated hGPR35 TMH4 and TMH5 superimposed on the 
β2-AR crystal structure.  Each sets of 105 CM-calculated helices of TMH4 and TMH5 are 
superimposed intracellularly on their respective  helices of the β2-AR crystal structure (PDB ID: 
2RH1). 
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TMH6 
For TMH6, two independent CM calculation were performed in order to create a TMH6 
that was representative of either an inactive (R) and active (R*) bundle. For the inactive (R) 
bundle the backbone dihedral ranges were restricted to ranges found within the crystal structure 
ranges for TMH6 (Table 3) and the χ1 of F6.48(230) was restrained to a g+ conformation (-
60°±40°). The CM calculations for the inactive bundle (R) suggest that the extracellular end of 
GPR35 TMH6 is very similar to that of the β2-AR. The bend, wobble angle, and face shift of the 
β2-AR, with P6.50 used as the “hinge residue”,  were 33.2°, -72.9°, and 85.0°, which correlated 
well to the average of 105 CM structures for TMH6 of GPR35 (26.68° ± 5.84°, -108.82°± 44.29° 
and 54.44° ± 18.69°).  Additionally, the CM TMH6 helices with increased flexibility also did not 
diverge from the crystal structure template, although as expected had larger standard deviations. 
The more flexible TMH6 had a bend, wobble angle, and face shift of 25.46° ± 9.11°, -65.15°± 
125.50° and 37.73° ± 28.85°. 
 
TMH4 
GPR35 lacks the Proline found at position 4.60 (P4.60 β2-AR, R4.60 GPR35) of the crystal 
structure template. The CM calculations for TMH4 show a variability in the face shift, bend  
angle,  and  wobble  angle  (1.63° ± 11.83°,  18.04° ± 4.95°,   and -123.39° ± 58.70°) of GPR35 
conformers vs. the β2-AR (48.0°, 40.0°, and  26.2°) using V4.58 as the “hinge residue” and the 
range of superimposition of i-4 and i+10 residues. If W4.50(141) is used as the “hinge residue”, 
the average of GPR35 TMH4 CM calculations (12.72° ± 7.90°, 7.46° ± 5.05°, and -9.26° ± 
111.47°) and β2-AR crystal structure (8.4°, 8.5°, and 70.3°) yield very different results. These 
numbers suggest that the lack of a Proline at 4.60 causes a local change at the extracellular 
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portion of TMH4 which leans towards the extracellular region of TMH5 compared to the β2-AR 
crystal structure (Figure 15).  
Induced 3-10 helical region in TMH7 
 
Adjusting the backbone dihedrals of the region S7.39(262) - D7.43(266) (7.39 - 7.42: Φ 
and Ψ, 7.43: Φ only) to match the homologous sequence found in the A2-AR (A2-AR: 
S7.42(277), H7.43(278), T7.44(279), N7.45(280), S7.46(281) vs. GPR35: S7.39(262), 
K7.40(263), L7.41(264), S7.42(265), D7.43(266)) induced a 3-10 helical region in the GPR35 
TMH7. This alteration in the helix shifted the position of the charged residue K7.40(263) from a 
lipid environment (Figure 16A), to a more energetically favorable position facing into the 
hydrophilic channel between helices TMH1, 2, and 3 (Figure 16B).  Additionally, this induced 3-
10 helix also shifted the extracellular position of TMH7 towards the extracellular top of TMH6 
(Figure 17), reducing the energetically unfavorable gap between these helices (Figure 18).   
 
 
Figure 16. Comparison of a hGPR35 bundles with either a CM-Calculated TMH7 or a TMH7 with 
an induced 3-10 helical region. A) hGPR35 bundle with CM-calculated TMH7 B) hGPR35 bundle 
with CM-calculated TMH7 with an induced 3-10 helical region (7.39-7.42: φ and ψ, 7.43: φ only) 
matching the analogous sequence in the A2-AR crystal structure (PDB ID: 2EML) 
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 Figure 17. Overlay of the initial CM-calculated TMH7 and the same CM TMH7 with 
an induced 3-10 helical region (superimposed intracellularly). 
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Figure 18. Comparison of the minimized TMH region of GPR35 R bundles with either a CM-
Calculated TMH7 or a TMH7 with an induced 3-10 helical region. Both the bundle with an initial 
TMH7 that was the original CM-calculated TMH7 (A) or the TMH7 with an induced 3-10 helical 
region (B) are depicted in both a molecular surface and as ribbons. The yellow circles identify the 
gap in the molecular surface of the protein between TMH6 and 7.   
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Minimized Human GPR35 R Bundle 
 
Biophysical data suggest two specific characteristics that are nearly universally 
associated with an inactive (R) GPCR bundle: the aromatic toggle switch residues 6.48 and 6.52 
in a χ1 = g+ conformation and an ionic lock between residues E(D)6.30 and R3.50. The 
minimized hGPR35 R bundle possesses these representative characteristics, with the toggle 
switch residues F6.48(230) and H6.52(234) in a χ1 = g+ conformation (Figure 19B) and a 
hydrogen bond between T6.30(212) and R3.50(114) (Figure 19A). While GPR35 does not have a 
negatively charged residues at position 6.30, experimental D6.30N(338) mutation data of the 
cannabinoid CB1 receptor suggest that the interaction between a hydrogen bond accepting residue 
and R3.50 is a mimic of the ionic lock between D6.30 and R3.50 [87]. This is further 
substantiated by mutational studies involving the μ‐opioid receptor, which identifies the residues 
that emulate the ionic lock of the R state of prototypical GPCRs as T6.34(279) and R3.50(165) 
[88].  In addition, R3.50 is in a highly conserved conformation with specific interactions, known 
as an arginine-cage motif [89], and is positioned between D3.49 and T6.30. This highly 
conserved arginine-cage motif is mimicked in the hGPR35 R bundle (Figure 19A).   
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A network of aromatic residue interactions found in the crystal structures of the β2-AR 
[31] and human dopamine D3 receptor [10] between the residues 5.47, 5.48, and 6.52 
(GPR35:F5.47, Y5.48, H6.52 vs. D3/A2-AR F5.74, Y5.48, F6.52) was also mimicked in the 
inactive hGPR35 bundle ((Figure 20). Importantly, the position of H6.52(234) in this mimicked 
aromatic network reduces the size of the binding pocket, which does not allow the agonists 
Zaprinast and pamoic acid to fit in the R bundle without major steric overlap, but does not affect 
the ability to dock the antagonist, MLS-0370945.  
 
 
Figure 20. Depiction of the aromatic stacking network between the residues F5.47, Y5.58, and 
F/H6.52. These depictions are from (A) the dopamine D3 receptor crystal structure (PDB ID: 3PBL),  
(B) the β2-AR crystal structure (PDB ID: 2RH1) and (C) the minimized hGPR35 R bundle 
Figure 19. Interactions/Rotameric states of conserved residues of the minimized hGPR35 R Bundle 
which are suggested to be representative of the inactive state. The representative states are (A) the 
highly-conserved arginine-cage motif (GPR35: D3.49 (113), R3.50 (114), and T6.30 (212)) and (B) ) 
the  χ1 = g+ of the toggle switch residues H6.52(234) and F6.48 (230).  
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The final set of residue-residue interactions that were implemented in the hGPR35 R state 
model was the aromatic stack between Y7.53(276) and F7.60(283), as suggested in the rhodopsin 
crystal structure [4] and by 5HT2C mutation studies [77]. The aromatic stack in GPR35 is a 
tilted-T π stack, which differs from the offset parallel interaction between these residues found in 
the Rhodopsin crystal structure (Figure 21). 
 
 
Following the minimization of the hGPR35 R bundle, the residue C(305), located on the 
C-terminus, was palmitylated. This post translational modification is found experimentally to 
occur in multiple Class A GPCRs, including rhodopsin [90], β2-AR [91], and the A1-AR [92]. 
Palmitoylation is the attachment of the 16 carbon-chain, saturated fatty acid palmitic acid to a 
cysteine via an acyl thioesterification. . The attached palmitic acid is suggested to act as an 
anchor, holding the C-terminus of the GPCR in the phospholipid bi-layer via the hydrophobic 
interactions betyween the palmitate and lipid of the fatty acid chains [93] .  
Figure 21. Depiction of the aromatic stack between the residues Y7.53 and F7.60. These are
depictions are from the (B) rhodopsin crystal structure (PDB ID: 1GZM) and in the (A)
minimized R state of hGPR35 
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Minimized Human GPR35 R* Bundle 
 
There are two characteristics that are associated with an active (R*) vs. an inactive (R) 
bundle: : 1) the χ1 rotameric change of aromatic toggle switch residues at positions 6.48 and 6.52 
and 2) the breaking of the intracellular ionic lock between the residues E(D)6.30 and R3.50. In 
order to emulate these characteristics, TMH6 of the R bundle was replaced with a different, 
structurally divergent CM TMH6 that was superimposed extracellularly. After the transition of 
F6.48(230) from a χ1 = g+ to a trans conformation, an offset parallel π-stack was formed 
between F5.47(180) and F6.48(230) (Figure 22A), which is suggested to stabilize the R* state in 
multiple GPCRs [28]. Figure 22B shows the overlaid images of the inactive bundle, with the 
toggle switch residues F6.48(230) and H6.52(234) in χ1 = g+ conformations (transparent), and 
the active bundle, with these residues in a χ1 = trans conformation.. This overlay demonstrates 
the large shift in bulk associated with this change. Furthermore, the electrostatic interaction 
between the residues T6.30(212) and R3.50(114) is broken in the activated hGPR35 bundle 
(Figure 22C). The distance of the Cα atoms of residue T6.30(212) between the active and inactive 
bundle was measured as 4.83 Å. This value is  analogous to the 5 Ǻ shift of the extracellular end 
of TMH6 (residues A(241) and R6.35(252)) during the activation of Rhodopsin, as measured by 
double electron-electron resonance (DEER) spectroscopy [18].  Additionally, D3.49(113) is 
protonated [81-82] and R3.50(114) is no longer in an arginine-cage motif, , as suggested by 
crystal structure data for opsin [6], metarhodopsin II [5, 94],  and the nanobody-stabilized active 
state of the β2-AR [8]. Also, the aromatic π stack between Y7.53(276) and F7.60(283) was 
disrupted in the GPR35 R* bundle (Figure 23A), due to the transition of the χ1 of Y7.53 from 
trans to g+ during activation, as suggested in the opsin crystal structure (Figure 23B). 
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Figure 23. The loss of the aromatic stack between Y7.53 (306) and F7.60 (313) in the Opsin (B) 
crystal structure (PDB ID: 2CAP) is mimicked in (A) the minimized hGPR35 R* Bundle. 
 
Minimized Human GPR35 R6.58A(240) Mutant Bundle 
 
I propose that the mutation of the residue R6.58(240) to an alanine will cause notable 
changes in the TMH4-5-6 interface, the proposed binding pocket for the ligands zaprinast and 
pamoic acid. The residue R6.58(240) in human GPR35 resides on the most extracellular α-helical 
loop of TMH6, facing the protein interior. In the wild-type human GPR35 bundle absent a ligand, 
the hydrophobic segment of the R6.58(240) side chain  fills the gap between the extracellular-
tops of TMH6 and TMH7. This position points the guanidinium group of R6.58(240) towards an 
area that in a complete cell would contain phospholipid head groups and/or be flooded with 
water. Mutating R6.58(240) to an alanine creates a large empty space between the extracellular-
ends of TMH6 and TMH7.  I propose that this unfavorable empty space is to be filled by the 
Figure 22. Interactions/Rotameric states of conserved residues of the minimized hGPR35 R* bundle 
which are suggested to be representative of an active state. The representative states are (A) the 
aromatic stacking of F5.47 (180) and F6.48 (230), (B) ) the  χ1 = trans of the toggle switch residues 
H6.52(234) and F6.48 (230) overlaid on the inactive bundle, and (C) the breaking of the electrostatic 
interaction between R3.50 and T6.30. 
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juxtaposed residue R7.32(255).  In the absence of the R6.58(240) bulk in the alanine mutant, 
R7.32(255) is able to adopt an alternative low energy conformation which fills the hole between 
the tops of the helices, while still exposing the guanidinium group to the extracellular, polar 
environment.      
Minimized rat GPR35 R* Bundle 
 
Rat GPR35 shares a 72% sequence identity with the human orthologue, with high identity 
in the TMH region, which suggests that their structures may be  similar. To create the rat GPR35 
model the human GPR35 R* bundle was mutated to match the rat GPR35 sequence with the 
following two exceptions: 1) first the TMH5 was replaced with the β2-AR TMH5 mutated to the 
rat sequence and 2) second the original EC2 loop was replaced with a new loop generated by 
MODELLER. A sequence difference at residue position 5.43, a non-conserved proline in human 
and serine in rat, causes gross structure difference between rat and human GPR35. This sequence 
difference causes a 3.91 Å relative shift in the extracellular end of the TMH5 of the minimized 
rGPR35 wild-type bundle, as compared to the analogous TMH5 of the hGPR35 bundle (Figure 
24B). This structure variation causes differences, which will be elaborated on in the following 
sections, in the docking positions of pamoic acid and zaprinast.  
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Figure 24. Comparison of the extracellular top of TMH5 in a minimized R* rGPR35 vs. hGPR35 
bundle. A) Minimized hGPR35 R* bundle with the carbon atoms (side chain and Cα) of the non-
conserved proline, P5.43 (160), colored in yellow B) Minimized rGPR35 R* bundle overlaid on the 
minimized hGPR35 R* bundle, with the noted relative shift of the position of the extracellular top of 
the rGPR35 TMH5 of 3.91 Å (distance measured from Cα of residue 5.39)    
 
Conformational Analysis of GPR35 Ligands 
Zaprinast 
 
 As displayed in Figure 25, zaprinast has 4 rotatable bonds: the bond connecting the phenyl 
and propoxyl substituents (3), two within the propoxyl substituent (1 and 2), and the bond 
connecting the propoxyphenyl and azapurine-6-one functional groups (4). Each rotatable bond 
was explored systematically with a 6-fold rotation, with low energy conformers 
calculated via a MMFFs force field. Each unique structure within 15 kcal/mol was 
evaluated at the ab initio Hartree Fock (HF) level of theory. These calculations suggested 
that the rotatable bonds at positions “1”,”2”, and “3” may adopt multiple low energy 
conformations at physiological temperatures [95]. 
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The four low energy conformers are all within approximately 2 kcal/mol of the global 
minimum, with variable low energy rotamers of either g+ ,g-, or trans at the rotatable bonds 
“1”,”2”, and “3” (Figure 26). The global minimum conformer has all three rotatable bonds of the 
propoxyphenyl group in a trans conformation. The second low energy conformer, which has an 
equivalent ”mirror”, adopts a gauche rotamer, either g+ or g-, at the rotatable bond “1”. The third 
low energy conformer adopts a g+ rotameric state for the “2” and “3” bonds and a trans 
conformation for bond “2”. The fourth conformer has a g+, g+, and trans rotamer at the “1”, “2”, 
and “3” bonds, respectively.  
 
Figure 26. The four low energy conformers of Zaprinast calculated at the HF 6-31+G* level of
theory. Values were calculated as implemented in Spartan ’08 (Wavefunction, Inc., 18401 Von
Karman Ave., Suite 370, Irvine, CA 92612). 
 
 
Figure 25. The rotatable bonds of 
zaprinast.
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Zaprinast has multiple possible tautomeric states and each was evaluated using two 
different theories: the Hartree Fock and Density function theory (DFT). For the initial 
calculations both theories utilized the basis set 6-31+G*. To fully explore the tautomeric states of 
zaprinast a second set of calculations, with a larger basis set of 6-311+G** and 6-311++G** for 
HF and DFT calculations, respectively, were performed.  Both theories identified the same low 
energy tautomers (Figure 27), though they differed in both the energy-based order and the 
energetic cost of tautomerization. Each tautomeric state has varied protonation state of the 
nitrogens on the azapurine-6-one functional group, and are defined as tautomers “A”, “B”, and 
“C”, with respective IUPAC names of  5-(2-Propoxy-phenyl)-3,6-dihydro-[1,2,3]triazolo[4,5-
d]pyrimidin-7-one, 5-(2-Propoxy-phenyl)-2,6-dihydro-[1,2,3]triazolo[4,5-d]pyrimidin-7-one, and 
5-(2-Propoxy-phenyl)-1,6-dihydro-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Figure 27). The HF 
level of theory at both basis sets identifies the sequence, in order of increasing energies, as 
tautomer “A”, “B”, then “C”. There is an approximate 1.5 kcal/mol energy difference between 
each tautomer (Table 5).  
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Figure 27. The three low energy tautomers of Zaprinast as calculated at the HF/DFT level of
theory.  Values were calculated as implemented in Spartan ’08 (Wavefunction, Inc., 18401
Von Karman Ave., Suite 370, Irvine, CA 92612), with IUPAC names of (A) 5-(2-Propoxy-
phenyl)-3,6-dihydro-[1,2,3]triazolo[4,5-d]pyrimidin-7-one, (B) 5-(2-Propoxy-phenyl)-2,6-
dihydro-[1,2,3]triazolo[4,5-d]pyrimidin-7-one, and  (C) 5-(2-Propoxy-phenyl)-1,6-dihydro-
[1,2,3]triazolo[4,5-d]pyrimidin-7-one 
 
Table 5. The energy and energy comparison of multiple, low-energy tautomeric states of Zaprinast 
at various levels of theory/basis sets. Values were calculated as implemented in Spartan ’08 
(Wavefunction, Inc., 18401 Von Karman Ave., Suite 370, Irvine, CA 92612). 
59 
 
The energy-based sequence using DFT identifies tautomer “B” as the global minimum, 
with the higher energy structures identified as “A” then “C”.  DFT calculates between a 0.3 and 
0.58 kcal/mol difference, depending on the basis set, from the global tautomer “B” to the first low 
energy tautomer “A” (Table 5).  Though these theories propose different global tautomers, both 
suggest the energy difference is small enough between them to expect each at physiological 
temperatures.  
Pamoic Acid 
As depicted in Figure 28, pamoic acid has 6 rotatable bonds: the two bonds “1” and “2” 
connecting the 3-hydroxy-naphthalene-2-carboxyl functional groups, the bonds connecting the 
carboxyl groups to its respective 3-hydroxy-naphthalene group, bonds “3” and “4”, and bonds 
connecting each hydroxyl group to its respective ring system, bonds “4” and “5”.  Pamoic acid 
has a pka2 of approximately 2.1, so it was analyzed as a di-anion to represent its likely 
physiological protonation state. Conformational analysis of this ligand, utilizing the HF level of 
theory with a 6-31+G* basis set in vacuum, calculated that the next lowest energy conformer 
from the global conformation was 7.84 kcal/mol greater in energy. To fully explore this di-anion, 
Figure 28. The rotatable bonds of pamoic acid. 
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 a conformational analysis was also performed at HF 6-31G* with a SM8 water solvation model. 
These calculations identified the identical global conformation as determined in vacuum, but also 
identified two conformers within 4 kcal/mol from the global minimum (Figure 29).  
 
 
Figure 29. The three low energy conformers of pamoic acid calculated at the HF 6-31+G* level of 
theory with the SM8 water solvation model. Values were calculated as implemented in Spartan ’08 
(Wavefunction, Inc., 18401 Von Karman Ave., Suite 370, Irvine, CA 92612). 
 
 
MLS-037094 
 
As shown in Figure 30, the compound MLS-0370945 has 9 rotatable bonds located 
throughout the molecule. The initial quantum mechanical assessment of this compound using HF 
6-31+G* in vacuum suggested that the molecule only adopted a folded conformation (Figure 31: 
conformer A), with the lowest energy elongated conformer being 9.79 kcal/mol higher in energy 
than the global minimum. The HF 6-31+G* energies recalculated with the addition of solvation 
energy using a  SM5.4/A water solvation model, [96] as implemented by Spartan ’08  
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(Wavefunction, Inc., 18401 Von Karman Ave., Suite 370, Irvine, CA 92612), suggested that a 
more elongated structure was only 1.62 kcal/mol higher in energy than the calculated global 
minimum.  This finding provoked a more thorough analysis, in which an equilibrium geometry 
optimization was calculated at HF 6-31+G* using a Poisson-Boltzmann water solvation model as 
encoded in Jaguar (version 9.0, Schrodinger, LLC, New York, NY) for the three low energy 
conformers calculated at HF 6-31+G* using a SM5.4/A water solvation model. The results of the 
calculations using the Poisson-Boltzmann water solvation model (Figure 32) suggests that the 
more elongated conformation is substantially lower in energy than the folded conformation.  The 
elongated conformer (Figure 31: Conformer B) after optimization was calculated as the 
minimum, while the two more folded conformers (Figure 31; A and C) were driven to the same 
higher energy conformation during the equilibrium geometry optimization. These results (Figure 
32) suggest that in water the more elongated conformer is 5.62 kcal/mol lower in energy than the 
more folded low energy conformer.  
 
 
 
Figure 30. The rotatable bonds of the compound MLS-0370945. 
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Figure 31. The three low energy conformers of the MLS-0370945 compound calculated at the HF 6-
31+G* level of theory (Vacuum vs. SM5.4/A water solvation model).  Values were calculated as 
implemented in Spartan ’08 (Wavefunction, Inc., 18401 Von Karman Ave., Suite 370, Irvine, CA 
92612), with the addition of the individual energies and the comparative energies in vacuum vs. the 
SM5.4/A water solvation model. 
 
 
 
Figure 32. The two low energy conformers of the MLS-0370945 compound calculated at HF 6-31+G* 
with the Poisson-Boltzann (PB) water solvation model. Values were calculated as implemented in 
Jaguar (version 9.0, Schrodinger, LLC, New York, NY), with the addition of the individual energies 
and the comparative energy. 
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Docking studies of GPR35 Ligands  
 
For the ligands of pamoic acid, zaprinast, and the compound MLS-0370945, the 
conformations that were considered for docking purposes did not exceed 5 kcal/mol above the 
global minimum, as this range is suggested to consider ligand conformations that make up the 
vast majority of the ligands’ biologically relevant conformations [95].   
MLS-037094 
 
Human GPR35 R Bundle 
The minimum energy conformation of the MLS-0370945 compound, as calculated using a 
HF 6-31+G* level of theory with a Poisson-Boltzmann water solvation model, was used as the 
initial manually-docked structure. After the protein-ligand optimization, the MLS-0370945 
compound has a large number of interactions with multiple residues (Figure 33). The total 
protein-ligand “energy of interaction” (EOI) was calculated as -71.32 kcal/mol, with similar EOI 
contributions from electrostatic and Van der Waals interactions, with approximate values of 44% 
and 56%, respectively (Table 3A). The largest contributing residue-ligand EOIs are from the 
arginine residues R4.60(151) and R(164), which form a salt bridge and a hydrogen bond, 
respectively, with the ligand. Multiple other residues contribute substantially to the total protein-
ligand EOI, including the residues Q3.29(93), Y3.32(96), H6.52(234), L6.55(237), R6.58(240), 
R7.32(255), and the EC2 loop residue F(163) with respective EOI of -6.62, -5.10, -3.34, -4.96, -
3.88, -3.73, and -4.01 kcal/mol. Each of the aforementioned residues interacts mainly with the 
MLS-0370945 compound via Van der Waals interactions. The ligand incurred a small 
conformational change during the minimization, with a conformational cost of docking of 1.23 
kcal/mol (Table 6A). GPCR crystal structures suggest that antagonists directly block the change 
of the rotameric conformation of either or both of the toggle switch residues at positions 6.48 and 
6.52. In the optimized MLS-0370945-hGPR35 R complex, the toggle switch residue H6.52(234)  
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Figure 33. The protein-ligand optimized dock of the MLS-0370945 compound in a minimized 
hGPR35 wild-type R bundle. The residues displayed represent an inclusive list of the residues that 
have an EOI magnitude of ≥ 3 kcal/mol. 
 
 
Table 6. The protein-receptor EOI of the MLS-03070945-hGPR35 R bundle. A) The total protein-
receptor EOI of the MLS-03070945-hGPR35 R bundle, with Van der Waals (VdW) and electrostatic 
contribution distributions, the ligand conformational cost of docking, and the experimental 
calculated IC50 (Molecular Libraries Probe Production Center at the Sanford-Burnham Institude, 
AID: 2079). B) An comprehensive list of all residue-ligand EOI that are ≥ 3 kcal/mol. 
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is locked in an inactive, χ1 = g+ conformation by the carboxyl functional group of the MLS 
compound, blocking the χ1 rotamer change of F6.48(230) (Figure 34). While there is no binding 
data for the MLS-0370945 compound, the low IC50 value of 71.8 nM would suggest that this 
compound would dock in the GPR35 R bundle with strong interactions, which correlates well 
with this docking study.  
 
Figure 34. The optimized MLS-0370945-hGPR35 R bundle which highlights that the MLS-0307045 
compound locks the hGPR35 in an inactive state. The position of the carboxyl functional group of the 
MLS-0307045 compound blocks the rotameric change of H6.52 (234), locking the GPCR in an 
inactive state. 
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Pamoic acid 
 
The initial conformation of pamoic acid for each manually-docked docking study was 
performed with the global minimum structure as calculated at the HF 6-31+G* level of theory. 
The strength of each residue-ligand EOI is depicted as a series of energy categories, with the 
displayed carbon atoms of each depicted residue identifying its particular category. The category 
with the largest magnitude has a range of 14.5 -12.0 kcal/mol, with the remaining 3 sequential 
categories having the same 2.5 kcal/mol range. Each total protein-ligand EOI includes the 
conformational cost of pamoic acid incurred during docking.    
 
Wild-type Human GPR35 R* 
In the optimized dock of pamoic acid in a wild-type GPR35 R* bundle (Figure 35) the total 
protein-ligand EOI is -78.16 kcal/mol, which has a slightly larger electrostatic component of 
approximately 60%. There are three individual ligand-residue EOIs, involving pamoic acid and 
the residues R3.36(100), R4.60(151), and R6.58(240), that contribute the majority of the total 
protein-ligand EOI, with an approximate combined contribution of 48%. The residues R3.36(100) 
and R6.58(240), which form salt bridges with the di-anionic pamoic acid, are the largest 
contributors with a combined approximate 34% of the total ligand-protein EOI, with 
corresponding EOI values of -13.70 and -12.97 kcal/mol.  Residue R4.60(151), which contributes 
approximately 14% (-10.87 kcal/mol) of the total EOI, forms a cation-π interaction with a 
naphthalene functional group of pamoic acid. Additional residue-ligand interactions occur 
between the residues S5.39(172), T(166), R(164), and F(163) and pamoic acid. Both S5.39(172) 
and T(166) donate hydrogen bonds to pamoic acid, while R(164) and F(163), both on the EC2 
loop, interact with pamoic acid mostly through mostly Van der Waals interactions.. Additionally, 
the ligand incurred a very minor conformational cost of docking of 0.04 kcal/mol (Table 7A). All 
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abovementioned residues, which all contribute -4.5 kcal/mol or less, are displayed in Table 7B, 
with both the values of the EOI and the types of interactions listed. Noted is that residue 
R7.32(255) is unable to interact with pamoic acid due to bulk of the juxtaposed residue, 
R6.58(240) (Figure 35).      
 
 
Figure 35. The protein-ligand optimized dock of pamoic acid in a minimized hGPR35 wild-type (WT) 
R* bundle. The residues displayed represent an inclusive list of the residues that have an EOI 
magnitude of ≥ 4.5 kcal/mol. The carbon atoms of each residue are colored in accordance with the 
magnitude of the residue’s EOI with the ligand. The residue R7.32 (255) (green), is not interacting 
with the ligand, but is displayed to identify its location and conformation in the hGPR35 WT 
R*bundle optimized with pamoic acid.  
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Table 7. The protein-receptor EOI of pamoic acid in a hGPR35 wild-type R* bundle. A) The total 
protein-receptor EOI of pamoic acid in a hGPR35 wild-type R* bundle, with Van der Waals (VdW) 
and electrostatic component distributions, the ligand conformational cost of docking, and the 
experimental calculated EC50s from (1) Jenkins et al. (2010) Biochem J, 2) Abood, M. Temple 
University, Unpublished data 3) Zhao et al. (2010) Mol Pharmacol 78) B) A comprehensive list of all 
residue-ligand EOI that are ≥ 4.5 kcal/mol. 
 
 
 
Human R6.58A Mutant GPR35 R* 
The optimized dock of pamoic acid in a R6.58A(240) mutant GPR35 R* bundle (Figure 
36) has a total protein-ligand EOI of -80.55 kcal/mol, with an approximate 61% electrostatic 
component (Table 8A). In the R6.58A(240)-pamoic acid dock, the three residues that contribute 
the majority of the total protein-ligand EOI are the residues R3.36(100), R4.60(151), and 
R7.32(255), with an approximate contribution of 43% of the total. The residues R3.36(100) and 
R7.32(255) both have salt-bridges with pamoic acid and contribute -13.48 and -12.28 kcal/mol, 
respectively. Similar to the wild-type dock, the R6.58A(240) mutant dock has a cation-π 
interaction between R4.60(151) and pamoic acid, which contributes a residue-ligand EOI of -8.65 
kcal/mol. Additional significant residue-ligand EOIs originate from the hydrogen bonds with 
pamoic acid and the residues S5.39(172) and T(166), and the Van der Waals interactions with the 
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ligand and the residues S(165) and R(164) on the EC2 loop. The residue-ligand EOIs of the 
ligand and the residues S5.39(172), T(166), S(165), and R(164) are -5.62, -7.00, -5.14, and -6.58 
kcal/mol, respectively. As compared to the total protein-ligand EOI, the conformational cost of 
docking was nearly insignificant, with a value of 0.08 kcal/mol (Table 8A). All of the 
aforementioned residues, which all have a minimum residue-ligand EOI magnitude of 4.5 
kcal/mol, are displayed in Table 8B, with both the values of the EOI and the types of interactions 
listed.  
 
 
Figure 36. The protein-ligand optimized dock of pamoic acid in a minimized hGPR35 R6.58A (240) 
mutant R* bundle. The residues displayed represent an inclusive list of the residues that have an EOI 
magnitude of ≥ 4.5 kcal/mol. The carbon atoms of each residue are colored in accordance with the 
magnitude of the residue’s EOI with the ligand.  The residue R6.58A (green), does not interaction 
with the ligand, but  is displayed to identify its position and bulk. 
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Table 8. The protein-receptor EOI of pamoic acid in a hGPR35 R6.58A(240) mutant R* bundle. A) 
The total protein-receptor EOI of pamoic acid in a hGPR35 R6.58A (240) mutant R* bundle, with 
Van der Waals (VdW) and electrostatic component distributions, the ligand conformational cost of 
docking, and the experimental calculated EC50s from (1) Abood, M. Temple University, Unpublished 
data B) A comprehensive list of all residue-ligand EOI that are ≥ 4.5 kcal/mol. 
 
 
 
 
Wild-type Rat GPR35 R* 
The final, optimized dock of pamoic acid in a wild-type rat GPR35 R* bundle (Figure 37) 
has a protein-ligand EOI of -64.65 kcal/mol, with an approximate 55% Van der Waals component 
(Table 9A). The two residue-ligand EOIs that contribute the most to the protein-ligand EOI are 
from the residues R4.60(148) and R3.36(97), with a 14% and 11% respective contribution. The 
residue R3.36(97) interacts with the ligand mostly electrostatically, with an EOI of -7.43 
kcal/mol. Similar to both of the hGPR35 docks, the residue R4.60(148) in rGPR35 interactions 
with pamoic acid via a cation-π interaction, with a residue-ligand EOI of -9.17 kcal/mol. Residues 
Y3.32(93), S5.38(169), and Q(163) all donate hydrogen bonds to the carboxyl functional groups 
of pamoic acid, while the residue F(160) on the EC2 loop interacts with the ligand via a mostly a 
Van der Waals interaction. The residue-ligand EOIs of residues Y3.32(93), S5.38(169), Q(163), 
and F(160) are –6.29, -7.01, -6.62, and –5.54 kcal/mol, respectively. The conformational cost of 
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docking was more substantial in the rGPR35 dock as compared to the hGPR35 docks, with an 
energy cost of 0.58 kcal/mol (Table 9A). Table 9B includes an inclusive list of the residue-ligand 
EOI with a magnitude equal to or greater that 4.5 kcal/mol, as well as the coordinated interaction 
type.  Noted is that there are no residue-ligand EOIs in the rGPR35-pamoic acid dock that meet 
the criterion of the first two energy categories, which is populated in both the human wild-type 
and R6.58A(240) mutant docks with pamoic acid. Also noted is that the relative position of 
pamoic acid is shifted in the wild-type rGPR35-pamoic acid dock, as compared to the analogous 
hGPR35 wild-type dock, with a relative shift of approximately 3Ǻ (Figure 38).  
 
 
Figure 37. The protein-ligand optimized dock of pamoic acid in a minimized rGPR35 wild-type R* 
bundle. The residues displayed represent an inclusive list of the residues that have an EOI magnitude 
of ≥ 4.5 kcal/mol. The carbon atoms of each residue are colored in accordance with the magnitude of 
the residue’s EOI with the ligand.   
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Table 9. The protein-receptor EOI of pamoic acid in a rGPR35 wild-type R* bundle. A) The total 
protein-receptor EOI of pamoic acid in a rGPR35 wild-type R* bundle, with Van der Waals (VdW) 
and electrostatic component distributions, the ligand conformational cost of docking, and the 
experimental calculated EC50 from (1) Jenkin et al. (2010) Biochem J B) A comprehensive list of all 
residue-ligand EOI that are ≥ 4.5 kcal/mol. 
 
 
 
 
 
 
 
Figure 38. The comparison of the position of pamoic acid in a optimized hGPR35 vs. rGPR35 wild-
type R* bundle. A) Pamoic acid docked (optimized) in a minimized hGPR35 wild-type R* bundle 
(blue) B) Minimized rGPR35 R* bundle (green) overlaid on the minimized hGPR35 R* bundle 
(transparent), with the noted relative shift of the position of pamoic acid in the rGPR35 (opaque) of 
2.96 Å (distance measured from the carbon atoms linking the rings of pamoic acid)    
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Zaprinast 
 
The initial conformation of zaprinast for each manually-docked, docking study was 
performed with the first low energy conformational and tautomeric state of zaprinast, as 
calculated at the HF 6-31+G* level of theory. The strength of each residue-ligand EOI is 
represented as described previously, using a series of energy categories. The category with the 
largest magnitude has a range of 6.0 - 4.8 kcal/mol, with the remaining 3 sequential categories 
having the same 1.2 kcal/mol range. Each total protein-ligand EOI includes the conformational 
and tautomeric cost of docking the ligand.   
 
Wild-type Human GPR35 R* 
Zaprinast docked in a human GPR35 R* bundle with optimized protein-ligand interactions 
(Figure 39) had a measured total protein-ligand EOI of -24.24 kcal/mol (Table 10A). The vast 
majority of the protein-ligand EOI between Zaprinast and the wild-type hGPR35 are from Van 
der Waals interactions, with an approximate 94% contribution. Noted is that there are no 
individual residue-ligand interactions that populate the first energy category. The interaction with 
the largest magnitude is the experimentally suggested [57] residue-ligand interaction between 
Y3.32(96) and Zaprinast, with a contribution of -3.92 kcal/mol, which is approximately 15% of 
the  protein-ligand EOI.  Another significant residue-ligand EOI is the tilted-T aromatic stack 
between F5.47(180) and Zaprinast, with a value of -3.25 kcal/mol. There are a series of leucines 
and a glutamine, L3.33((97), L6.51(233), L6.55(237), and Q3.29(93), that together contribute 
approximately 44% of the protein-ligand EOI with respective EOI values of -2.76, -3.07, -3.19, 
and -2.76 kcal/mol. The abovementioned residues proximity and EOI are visualized and listed in 
Figure 39 and Table 10B, respectively. Additional residue-ligand interactions include the mostly 
Van der Waals interactions between zaprinast and the residue R6.58(240) and the residue C(162), 
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located on the EC2 loop, with respective EOI values of -2.06 and -1.81 kcal/mol.  The 
comformational and tautomeric cost of docking was significant, with an energy of 2.77 kcal/mol 
(comformational: 1.13 kcal/mol, tautomeric: 1.64 kcal/mol) Noted is that the residues R7.32(255) 
and S7.39(262) (Figure 39) have little to no interaction with zaprinast, but their positions and 
interactions are integral to be able to explain the ligand binding difference in the R6.58A(240) 
mutant- specifically that in the wild-type dock S7.39(262) is hydrogen bonded to Y3.32(96).  
  
 
Figure 39. The protein-ligand optimized dock of Zaprinast in a minimized hGPR35 wild-type R* 
bundle. The residues displayed represent an inclusive list of the residues that have an EOI magnitude 
of ≥ 1.2 kcal/mol. The carbon atoms of each residue are colored in accordance with the magnitude of 
the residue’s EOI with the ligand.  The residues R7.32 (255) and S7.39 (262) (green) have little to no 
interaction with the ligand, but are displayed to identify their location and or interaction partners. 
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Table 10. The protein-receptor EOI of Zaprinast in a hGPR35 wild-type R* bundle. A) The total 
protein-receptor EOI of Zaprinast in a hGPR35 wild-type R* bundle, with Van der Waals (VdW) 
and electrostatic component distributions, the ligand’s conformational/tautomeric cost of docking, 
and the experimental calculated EC50s from (1)Taniguchi et al. (2006) Febs Lett 580(21), (2) Zhao et 
al. (2010) Mol Pharmacol 78(4),  (3) Abood, M. Temple University, Unpublished data, (4) Taniguchi 
et al (2008) Pharmacology 82(4), and (5)Jenkins et al. (2010) Biochem J B) A comprehensive list of all 
residue-ligand EOI that are ≥ 1.2 kcal/mol. 
 
 
Human R6.58A Mutant GPR35 R* 
The final optimized dock of zaprinast in a human R6.58A(240) mutant GPR35 R* bundle 
(Figure 40) had a calculated final protein-ligand EOI of -28.65 kcal/mol (Table 11A). Similar to 
Zaprinast docked in the human wild-type, the majority of the protein-ligand EOI in the 
R6.58A(240) mutant dock is from Van der Waals interactions, with an approximate 90% 
contribution. The residue-ligand EOI that has the largest magnitude is Y3.32(96), which is 
hydrogen bonded to Zaprinast, with an EOI of -5.47 kcal/mol. In addition to an electrostatic 
component, the Y3.32(96)-Zaprinast EOI also includes a largely contributing Van der Waals 
component. This residue-ligand EOI populates the highest energy category and contributes 
approximately 18% of the total protein-ligand EOI. A significant energy contribution also comes  
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Figure 40. The protein-ligand optimized dock of Zaprinast in a minimized hGPR35 R6.58A (240) 
mutant R* bundle. The residues displayed represent an inclusive list of the residues that have an EOI 
magnitude of ≥ 1.2 kcal/mol. The carbon atoms of each residue are colored in accordance with the 
magnitude of the residue’s EOI with the ligand.  The residue R6.58A (green) does not interaction 
with the ligand, but  is displayed to identify its position and bulk. 
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Table 11. The protein-receptor EOI of Zaprinast in a hGPR35 R6.58A (240)  R* bundle. A) The total 
protein-receptor EOI of Zaprinast in a hGPR35 R6.58A (240) R* bundle, with Van der Waals (VdW) 
and electrostatic component distributions, the ligand’s conformational/tautomeric cost of docking, 
and the experimental calculated EC50 from (1) Abood, M. Temple University, Unpublished data B) A 
comprehensive list of all residue-ligand EOI that are ≥ 1.2 kcal/mol. 
 
 
 
from the mostly Van der Waals interaction between the ligand and the residues Q3.29(93), 
L3.33(97), L6.51(233), L6.55(237), and F(163) on the EC2 loop with respective EOI values of -
4.01, -2.63, -2.94, -3.33, and -1.24 kcal/mol. The additional residue-ligand interactions that have 
a EOI magnitude of greater than 1.2 kcal/mol are a hydrogen bond with S7.39(262), a tilted-T 
aromatic stack with F5.47(180), and a cation-π interaction with R7.32(255), with the 
corresponding EOI of -2.69, -2.37, -1.24 kcal/mol. The energy cost of docking Zaprinast in the 
hGPR35 R6.58A(240) mutant was 2.27 kcal/mol (conformational: 0.63 kcal/mol, tautomeric: 
1.64 kcal/mol). Table 11 displays a quantitative synopsis of this dock, including the protein-
ligand EOI, the conformational and tautomeric cost of docking, and an inclusive list of the values 
of all residue-ligand interactions with a magnitude above 1.2 kcal/mol.  
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The cation-π interaction between zaprinast and R7.32(255) occurs between the propoxy-
benzyl functional group of zaprinast and the guanidinium group of R7.32(255) (Figure 41). The 
central carbon on the guanidinium group has a measured distance of 4.152 Ǻ from the plane of 
the benzene, which is similar to the computationally-determined ideal distance of 3.96 Ǻ for 
analogous molecules [97]. The angle of the involved N-H atoms of the guanidinium group of 
R7.32 and the benzene centroid of zaprinast was measured as 162.69°, which is comparable to the 
computationally-derived ideal angle of 180° [97].    
 
 
Figure 41. Depiction of the quantitative assessment of the cation-π interaction between R7.32(255) 
and Zaprinast in the optimized hGPR35 R6.58A mutant R* dock. This interaction is depicted from  
an extracellular top (A) and side perspective (B). The central carbon of the guanidinium functional 
group of R7.32 (255) has a distance of 4.152 Å from the plane of propoxy-benzyl functional group of 
Zaprinast and the angle of the involved N-H atoms of the guanidinium group of R7.32 and the 
benzene centroid of Zaprinast was measured as 162.69°. 
 
Wild-type Rat GPR35 R* 
The finalized, optimized zaprinast dock in a rat GPR35 R* bundle (Figure 42) has a 
measured total protein-ligand EOI of -31.58 kcal/mol. Similar to zaprinast docked in human 
GPR35, the type of non-bonded protein-ligand interaction that contributed the most towards the 
protein-ligand EOI in the rat dock was determined as Van der Waals interactions, with an 
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approximate 90% contribution. In the optimized rGPR35-zaprinast dock there are two residue-
ligand EOIs that populate the energy category with the largest magnitude, Y3.32(93) and 
L7.35(256). These two residues both individually contribute approximately 5 kcal/mol, and there 
summed residue-ligand EOIs contribute about 30% of the protein-ligand EOI.  Y3.32(93) donates 
a hydrogen bond to zaprinast, but the majority of the EOI for both the residues Y3.32(93) and 
L7.35(256) is due to Van der Waals interactions. S5.43(174) accepts a hydrogen bond from 
Zaprinast and has an residue-ligand EOI of -2.04 kcal/mol. Additionally, the residues Q3.29(90), 
L3.33(94), L6.55(235), Q6.58(238), L7.35(256), T7.36(257), and F(160) on the EC2 loop 
contribute approximately 62% of the protein-ligand EOI, mostly via Van der Waals interactions, 
with the respective residue-ligand EOIs of -3.09, -2.15, -3.35, -3.47, -5.08, -2.04, and -1.92 
kcal/mol. The conformational and tautomeric cost of docking of zaprinast were similar in the 
wild-type rat dock as compared to the human docks, with an energy cost of 2.31 kcal/mol 
(conformational: 0.67, tautomeric: 1.64 kcal/mol) (Table 12A).  Table 12 lists the total protein-
ligand EOI, the ligand conformational and tautomerization costs, and the EOI value and the type 
of interaction of all residue-ligand interactions with an EOI magnitude of greater than or equal to 
1.2kcal/mol. 
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Figure 42. The protein-ligand optimized dock of Zaprinast in a minimized rGPR35 wild-type R* 
bundle. The residues displayed represent an inclusive list of the residues that have an EOI magnitude 
of ≥ 1.2 kcal/mol. The carbon atoms of each residue are colored in accordance with the magnitude of 
the residue’s EOI with the ligand.   
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Table 12. The protein-receptor EOI of Zaprinast in a rGPR35 wild-type R* bundle. A) The total 
protein-receptor EOI of Zaprinast in a rGPR35 wild-type R* bundle, with Van der Waals (VdW) 
and electrostatic component distributions, the ligand’s conformational/tautomeric cost of docking, 
and the experimental calculated EC50s from (1)Taniguchi et al. (2006) Febs Lett 580(21), (2) Ohshiro 
et al. (2008) Biochem Biophys res commun 365(2), (3)Jenkins et al. (2010) Biochem J, and(4) 
Taniguchi et al (2008) Pharmacology 82(4) B) A comprehensive list of all residue-ligand EOI that are 
≥ 1.2 kcal/mol. 
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CHAPTER IV 
 
DISCUSSION 
 
 
The goal of this project was to build accurate GPR35 models to be able to suggest viable 
reasons for the pharmacological differences or similarities between human wild-type, rat wild-
type, and a R6.58A(240) human GPR35 mutant for the ligands pamoic acid and zaprinast. As no 
crystal structure is currently available for GPR35, a homology model was built using the crystal 
structures templates of β2-AR and A2-AR for the TMH region. Though GPR35 and these 
template GPCRs share many conserved residues/motifs, GPR35 has several non-conservative 
sequence differences. These non-conservative sequence differences, such as the lack of a proline 
in TMH7 in the highly conserved NPXXY motif, are suggested to cause gross differences in the 
TMH region of GPR35 vs. the crystal structure template. Important to note is that in GPCRs a 
sequence divergence, such a lack of a conserved proline near the center of a helical structure, is 
probable to not only cause major structure changes in the orientation of the extracellular positions 
of the divergent TMH, but will also affect the orientation of the juxtaposed helices. The 
implications of these sequence divergences were assessed using the Monte Carlo, simulated 
annealing technique, Conformational Memories (CM). This technique has corroborated that many 
of these non-conservative sequence divergences cause structural difference between GPR35 and 
the crystal structure templates.  
As mentioned earlier, the TMH7 of GPR35 lacks the NPXXY motif and instead has a 
sequence of DAICY. TMH7 was initially suggested to diverge the most severely from the 
template structures and therefore was assessed first. For GPR35, the lack of an NPXXY motif in 
appears create a much straighter TMH7 than the template structures. The shift in the extracellular 
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position of TMH7 is suggested by CM to be compensated for in the structure of GPR35 by the 
additional variation of a proline at 2.58 instead of at the locant 2.59 in TMH2.  These changes 
work together to yield a conformational difference in the TMH1-2-7 region of GPR35, but creates 
an overall cohesive receptor conformation. The lack of a conserved proline in TMH4 (P4.60) 
causes a conformational change in TMH4, moving the extracellular end of TMH4 closer to 
TMH5.  Such a conformational change would allow for a shorter EC2 loop, which is 
accommodated by the GPR35 sequence, as GPR35 has a shortened EC2 loop. These studies 
suggest that the influence of a single conformational change may be pervasive, but is ultimately 
compensated for by additional, sequence-dictated conformational changes in the approximal 
helices.    
After the initial development and minimization of the active forms of a human wild-type, 
human R6.58A mutant, and rat GPR35 models, docking studies were performed with the ligands 
pamoic acid and zaprinast. The assessment of each dock was based on the magnitude of each 
individual protein-ligand “energy of interaction” (EOI).  The calculated protein-ligand EOI may 
be representative of the actually binding affinity in physiological conditions, though several 
variables are unable to be considered in this experimental system. The impact that these variables, 
described below, would have on the EOI is assumed to be similar in each bundle with the same 
docked ligand. This hypothesis suggests that while the measured protein-ligand EOI may not be a 
direct reflection of the experimental binding energy of the ligand, the differences in energy of the 
comparative docks with the same ligand should be accurate representations of the differences in 
ligand-binding energy.  Essentially by comparing the protein-ligand EOI, in lieu of assessing 
them separately, the results are essentially normalized. Each set of comparisons described will 
evaluate the differences and similarities of the human wild-type docks vs. the rat wild-type or 
human R6.58A(240) mutant GPR35 docks.    
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The probable most-influential variable not able to be directly considered is the effect of 
the solvent. It is assumed that water permeates the TMH4-5-6 channel, though the number of 
water molecules is unknown and most likely transient. The concentration of water in the binding 
pocket would have multiple effects on the accurate measurement of the protein-ligand EOI.  One 
of the most prominent effects that water has on the strength of protein-ligand interactions lies in 
the ability of water to shield the electrostatic component of protein-ligand interaction. The 
amount of shielding of a solvent can be represented by a dielectric constant. The dielectric 
constant varies with different solvents, with examples of tetrachloro-methane, ethyl acetate, 
ethanol, and water having approximate respective dielectrics of 2.23, 5.99, 24.85, and 78.0 [98]. 
These values are canonical representations of a real solvent, as they represent stationary, 
completely homogonous bulk solvent.  There are multiple, more accurate ways of representing 
solvent effects, such as the Generalized Born with solvent accessible surface area solvation model 
(GBSA) [99]. The GBSA model considers not only the shielding affect of the solvent,  but also 
considers the energy cost of creating a hole in an equilibrated solvent, the energy of the 
polarization of the solvent, and the surface accessibility of the molecule of interest to the solvent. 
Unfortunately implicit solvation models, such as the GBSA model, require that the molecule of 
interest be in a bulk solvent, which would make this model ineffectual for determining the solvent 
effects on ligands docked in the current GPR35 model.  For these reasons, the method used to 
emulate the effects of water on the protein-ligand EOI only considered the shielding effect. A 
distance-dependent dielectric, which increases with distance, was used to represent the 
electrostatic dampening effects of water on the protein-ligand interactions. The fundamental 
concept of why a distance-dependent dielectric can emulate the shielding effects of water is that 
once the distance between two atoms reaches a threshold distance, the dielectric will be equal to 
the high-dielectric of bulk water. The dielectric constant of the distance-dependent dielectric 
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chosen for the protein-ligand minimizations and the EOI calculations was three. There have been 
a variety of dielectric constants chosen to represent the interior of GPCRs, including the dielectric 
constants of 1 [100], 2 [101] 4 [102-103] , and 5 [104]. The value of three was chosen for the 
analysis of GPR35, as it is representative of the literature values.        
The first sets of docks to be compared are the human wild-type docks vs. the rat wild-
type GPR35 docks. There is pharmacological experimental data for both human and rat GPR35 
that measure the potency of both the ligands pamoic acid and zaprinast. These potencies, which 
are from experiments performed by collaborators and other research groups, show a strong 
continuity in the measured potency between groups (Table 13). The potencies of pamoic acid for 
human wild-type vs. rat wild-type GPR35 are significantly different from one another (Table 
13A), with an average EC50 value of approximately 61 nM for human wild-type and an EC50 of 
greater than 100 μM in rat wild-type GPR35. Important to note is that though pamoic acid had a 
significantly lower potency in rat GPR35, there was detected activation [57]. Unpublished results 
(Mary Abood, Temple Univeristy) also suggested a similar trend with pamoic acid at mouse 
GPR35, with an approximate EC50 of 5μM. Mouse and rat GPR35 have an 85% identity, with an 
identical match of all of the suggested primary interaction residues between pamoic acid and 
rGPR35, including a serine at 5.43. The dose-dependent antinociceptive effect of pamoic acid 
was also detected in vivo in mouse, but with the large A50 of 40.5 mg/kg [59].  The large sequence 
identity between mouse and rat GPR35, particularly the fact that the suggested direct interaction 
residues in rat are identical between species, strongly suggests these results in mouse would 
parallel those in rat. The potency of zaprinast is also variable between human and rat GPR35. The 
EC50 values for zaprinast have been calculated by multiple experimental groups, with a 
statistically significant difference (p < 0.001) of EC50s between species, with an approximately 62 
fold increase in rat over human GPR35 [57].   
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Table 13. EC50s identified for pamoic acid and Zaprinast in human and rat wild-type GPR35. A) 
EC50s identified for pamoic acid in human and rat wild-type GPR35 from (1) Jenkins et al. (2010) 
Biochem J, (2)  Abood, M. Temple University, Unpublished data, and (3) Zhao et al. (2010) Mol 
Pharmacol 78(4) B) EC50s identified for Zaprinast in human and rat wild-type GPR35 from 
(1)Taniguchi et al. (2006) Febs Lett 580(21), (2) Zhao et al. (2010) Mol Pharmacol 78(4), (3) Abood, 
M. Temple University, Unpublished data, (4) Taniguchi et al (2008) Pharmacology 82(4), (5) Jenkins 
et al. (2010) Biochem J, and (6) Ohshiro et al. (2008) Biochem Biophys res commun 365(2  
*Denotes statistically significant difference (p < 0.0001) 
 
 
 
 Comparison of the EOIs of the human and rat wild-type GPR35 docks with pamoic acid 
offer an explanation for these substantial interspecies potency differences of pamoic acid. Pamoic 
acid has an increase of 14.09 kcal/mol in rat GPR35 as compared to human (Table 14).  As a 
larger, or less negative, EOI value represents a weaker protein-ligand interaction, the increase of 
approximately 14 kcal/mol represents a substantially reduced protein-ligand interaction of pamoic 
acid in rat as compared to human GPR35. This divergence can be mostly attributed to a small 
number of residue-ligand interaction differences, involving residues at positions 3.36, 6.58, and 
the residue on the EC2 loop that is two positions past the cysteine that forms a conserved 
disulfide bridge with C3.25. As noted in earlier, rat GPR35 does not have any residue-ligand EOI 
that are greater than 9.5 kcal/mol (Table 9B), while the human wild-type GPR35 dock has three 
(Table 7B and Table 8B). A justifiable reason that the rat dock lacks residue-ligand interactions at 
these energy levels, while human GPR35 does, is that rat sequence lacks the positively charged  
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residues at loci 6.58 and 7.32 found in the human sequence. Rat GPR35 has a glutamine and 
serine at the respective positions of 6.58 and 7.32, and therefore cannot form a salt bridge with 
pamoic acid at these positions. Additionally, the EOI of R3.36 and pamoic acid in the rat GPR35 
dock has a substantially lower magnitude as compared to the human docks, with values of -7.43 
kcal/mol for rat and  approximately -13.5 kcal/mol for the human docks. This difference is 
suggested to be caused by the shift of the final docked position of pamoic acid in rat GPR35 as 
compared to human GPR35 (Figure 38B). As described earlier, rat GPR35 lacks the non-
conserved proline found in hGPR35 at position 5.43, which causes an approximate 4 Ǻ relative 
shift in the extracellular position of TMH5 (Figure 24B).  This change in the position of TMH5 is 
proposed to be the cause of the relative docking position shift of pamoic acid by approximately 3 
Ǻ.  This shift increased the relative distance between R3.36 and pamoic acid in rat GPR35 as 
compared to hGPR35, which mitigated the residue-ligand EOI.  
A comparison of the interactions of R3.36 and pamoic acid between the human wild-type 
and rat wild-type GPR35 docks (Figure 43) shows that the position of pamoic acid in rat does not  
Table 14. The listed comparisons of the EOIs of pamoic acid docked (optimized) in the human 
and rat GPR35 minimized R* bundles. The displayed residues are an inclusive list of residues 
that have a ≥ 2 kcal/mol residue-ligand EOI difference. 
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Figure 43. The comparison of the R3.36-pamoic acid residue-ligand interactions in both the 
minimized human (A) and rat (B) wild-type GPR35 R* bundles optimized with the ligand pamoic 
acid. 
 
allow for as strong of an interaction with R3.36(97), but is instead replaced with an energetically 
weaker hydrogen bond with the juxtaposed residue Y3.32(93). The final substantial residue-
ligand energy difference lies with the residue on the EC2 loop that is two positions past the 
conserved cysteine that forms a disulfide bridge with C3.25. The residue at this position, which is 
experimentally suggested to face into the TMH4-5-6 interface by SCAM studies in the dopamine 
D2 receptor [84] and by multiple crystal structures [9-11, 31], is an arginine in the human 
(R(164)) and a serine in rat GPR35 (S(161)). The residue-ligand interaction at this position is 
approximately 5 kcal/mol better in human GPR35 as compared to rat (Table 14).  
In summary, the suggested reason for the difference in the EC50 of pamoic acid in rat vs. 
human GPR35 is due to three residue sequence variations. The non-conserved proline found in 
human GPR35, P5.43(176), is absent in the rat sequence. This difference is suggested to cause the 
relative shift of the extracellular end of TMH5 approximately 4Ǻ, which in turn shifts the relative 
position of pamoic acid a similar distance.  This shift increased the distance between R3.36 and 
pamoic acid in rat GPR35 as compared to human, which mitigates their relative EOI. 
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Additionally, one of the residue-ligand EOI with the largest magnitude in hGPR35 is a salt-bridge 
between the residue R6.58 and pamoic acid. This residue is a glutamine in rGPR35, and therefore 
is not able to create the same strong interaction. Finally, an arginine on the EC2 loop in human, 
R(164), contributes, through mostly Van der Waals interactions, an approximately 5 kcal/mol 
better interaction with pamoic acid than the analogous residue, S(161), found in the rat sequence.  
There have been several experimental groups which have assessed the potency of the 
agonist zaprinast in both human and rat wild-type GPR35. These experimental studies (Table 
13B) have yielded a consistent trend of zaprinast having a higher potency in rat vs. human 
GPR35, with a statistically significant difference found in 2010 by Jenkins et al, with an 
approximately 60 fold increase in potency, with respective EC50 values of 0.047μM and 2.95μM. 
These differences in potency correlate with the differences in the calculated protein-ligand EOI, 
with an improved total EOI in the rat dock of -7.34 kcal/mol (Table 15). The suggested reasons 
for the interspecies difference in total protein-ligand EOI of zaprinast, which lacks a formal 
charge in physiological conditions, are more subtle that those found for the di-anion pamoic acid. 
The comparison of all residue-ligand EOIs that exceed a difference of 0.75 kcal/mol (Table 15) 
suggests that the majority of the approximate 8 kcal/mol difference originate from the EOI 
differences of the residues at positions 7.35, 7.36, and 5.43.  
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The most substantial interspecies EOI difference of -4.99 kcal/mol occurs at the residue 
L7.35 (human/rat, 258/256) (Table 15). While the residue at this position is a leucine in both rat 
and human GPR35, the cause of this significant EOI difference is a sequence difference at a 
proximal residue position. The residue at position 6.54, which in juxtaposition to L7.35, is the 
beta-branched amino acid isoleucine in rGPR35 and a glycine in hPR35.  In hGPR35 the lack of 
the bulk of G6.54(236) allows L7.35(258) to adopt the χ1 = g+ conformation, which allows for 
the Van der Waals interactions with the nearby residues I(254), V6.57(239), and T7.38(261) 
(Figure 44A). In rGPR35, the bulk of I6.54(234) forces L7.35(256) into a χ1 = trans 
conformation (Figure 44B), which places its bulk into the binding pocket, allowing for a direct 
interaction with zaprinast.  
 
 
Table 15. The listed comparisons of the EOIs of Zaprinast docked (optimized) in the human and 
rat GPR35 minimized R* bundles. The displayed residues are an inclusive list of residues that 
have a ≥ 0.75 kcal/mol residue-ligand EOI difference. 
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Figure 44. Comparison of the χ1 rotamer of L7.35 in hGPR35 vs. rGPR35. Residues are displayed in 
accordance to their Van der Waals radius. In hGPR35 (A) the lack of bulk of G6.54 (236) allows for 
L7.35 (258) to be in a χ1 = g+ conformation, allowing for favorable interactions with V6.57 (239),  
I(254), and T7.38 (261). This is opposed to rGPR35 (B), where the bulk of I6.54 (234) forces L7.35 
(256) into a χ1 = trans conformation, putting its bulk into the binding pocket.  
 
The basis for the interspecies EOI differences involving the residues at positions 7.36 and 
5.43 is more unambiguous, as the residues at these positions vary between species. In hGPR35, 
the residues at 7.36 and 5.43 are a tyrosine and non-conserved proline, respectively. In rGPR35, 
which has the more favorable residue-ligand EOIs of -2.04 and -1.82 kcal/mol at the coordinating 
residues of 7.36 and 5.43, has a threonine and serine at  these positions. In hGPR35 Y7.36(259) is 
only able to adopt a χ1 = trans conformation, due to the bulk of the surrounding residues, which 
negates the possibility of interacting directly with the ligand. The smaller T7.36(257) in rGPR35 
is in a χ1 = g+ conformation, which places the hydrophobic portion of the side-chain towards lipid 
and the hydrophilic segment towards zaprinast.  In rGPR35, the serine at position 5.43 accepts a 
hydrogen bond from zaprinast. This hydrogen bond between zaprinast and S5.43(174) in rGPR35 
partially directs the docked position of the ligand, which accounts for difference in the orientation 
of zaprinast in the human GPR35 dock as compared to the rat dock. 
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 Additional, significantly different interspecies residue-zaprinast EOIs that favor rGPR35 
occur at the positions 6.58, 3.32, and the position on the EC2 loop that immediately follows the 
cysteine involved in a disulfide bridge with C3.25. At position 6.58 in GPR35 the sequences are 
different between species, with this residue being an arginine in human and a glutamine in rat. In 
the hGPR35 dock, the guanidinium group of R6.58(240) is facing extracellularly, towards an area 
that in a complete cell would contain phospholipid head groups and be flooded with water. 
Though the charged portion of R6.58(240) is not interacting with zaprinast, the more hydrophobic 
region does contribute an EOI of -2.06 kcal/mol via Van der Waals interactions. The smaller, less 
polar Q6.58(238) is able to adopt a low energy conformation that is able to interact more 
substantially with zaprinast than the arginine found in hGPR35 at the analogous position, with an 
improved interaction of -1.41 kcal/mol.  The elevated EOI in rat vs. human GPR35 of -0.93 
kcal/mol occur at both the residues of Y3.32 (96/93, human/rat) and F (163/160, human/rat) on 
the EC2 loop. The altered position of zaprinast in the rGPR35 dock, due to the unique hydrogen 
bond between the ligand and S5.43, allows for the comparatively increased Van der Waals 
interaction at both Y3.32(93) and F(160).   
While the overall change in protein-ligand EOI difference between human and rat GPR35 
for zaprinast is approximately -8 kcal/mol, not all of the residue-ligand EOIs are better in rat. The 
residues as locants 5.47 and 6.51, which are a phenylalanine and a leucine, respectively, in both 
species, have EOI differences of -2.60 and -2.16 kcal/mol that favor the human dock. These 
differences are attributed to the relative change in position of zaprinast. In the human wild-type 
dock, zaprinast forms a tilted-T aromatic stack with F5.47(178), while in the rat dock this 
interaction is replaced by the hydrogen bond with S5.43(174). The change in the orientation of 
zaprinast to be able to retain the hydrogen bond with S5.43(174) also increases the relative 
distance of L6.51 in rGPR35 as compared to hGPR35, reducing the Van der Waals interaction. 
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An additional residue-ligand EOI that favors the human dock occurs at the cysteine on the EC2 
loop that is assumed to have a highly-conserved disulfide bridge with C3.25. This relative EOI 
difference of 1.27 kcal/mol is similarly attributed to the relative change in position of zaprinast in 
rat, due to the hydrogen bond with S5.43 (174). 
 In summary, these docking studies suggest that zaprinast has an increased binding 
affinity in rGPR35 as compared to hGPR35, with a calculated protein-ligand EOI of -7.34 
kcal/mol favoring rGPR35, which parallels the experimental data of other groups, which suggest 
that zaprinast has an increased potency of between 25 and 60 fold in rat as compared to human 
GPR35. The difference in the protein-ligand EOI is due to a multitude of differences in residue-
ligand EOIs including: 1) the increased Van der Waals interactions in rGPR35 at residues 
Y3.32(93) and F(160) due to the relative change in position of zaprinast, 2) a hydrogen bond 
between zaprinast and S5.43(174), which is only possible in rGPR35 due to a sequence 
difference, 3) an increase in the Van der Waals interaction at between zaprinast and the residues 
at the positions 6.58 and 7.36, due to a direct sequence difference, 4) the increased Van der Waals 
interactions of zaprinast and L7.35 in rGPR35, due to L7.35(256) forced rotamer of χ1 = trans 
caused by the bulk of the juxtaposed I6.54(234), and 5) the comparatively mitigated EOIs in 
rGPR35 with the residues F5.47(178), L6.51(231), and the highly-conserved cysteine on the EC2 
due to the relative position change of zaprinast.    
The final series of docking studies to be compared are between the wild-type and the 
R6.58A(240) mutant of human GPR35. Pamoic acid has shown to have a high potency in the 
hGPR35 wild-type, with similar EC50s from multiple groups and publications (Table 16A), with 
an average EC50 of approximately 60 nM. The EC50 of pamoic acid for the R6.58A(240) mutant 
was calculated as 62.3 nM (30.5 – 127) by collaborator Mary Abood (unpublished data), which 
showed a trend toward an increased potency from the wild-type, but was not statistically 
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significantly different.  Zaprinast is moderately potent at the hGPR35 wild-type, with an 
approximate average EC50, as calculated by multiple groups (Table 16), of 1.8 μM. Contrasting 
pamoic acid, zaprinast in the R6.58A(240) hGPR35 mutant showed a statistically significant 
increased potency (p < 0.05) as compared with its wild-type counterpart, with a calculated EC50 of 
0.08 µM (Unpublished results, Mary Abood).   
 
Table 16. The EC50s identified for pamoic acid and Zaprinast in the human wild-type and the 
R6.58A(240) GPR35 mutant. A) The EC50s identified for pamoic acid in the human wild-type and the 
R6.58A(240) GPR35 mutant by (1) Jenkins et al. (2010) Biochem J, (2)  Abood, M. Temple 
University, Unpublished data, and (3) Zhao et al. (2010) Mol Pharmacol 78(4). B) The EC50s 
identified for Zaprinast in the human wild-type and R6.58A (240) mutant by (1)Taniguchi et al. 
(2006) Febs Lett 580(21), (2) Zhao et al. (2010) Mol Pharmacol 78(4), (3) Abood, M. Temple 
University, Unpublished data, (4) Taniguchi et al (2008) Pharmacology 82(4), and (5)Jenkins et al. 
(2010) Biochem J)  
* Denotes statistically significant difference (p < 0.05) 
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 The potency of the ligand pamoic acid is not statistically significantly different between 
the GPR35 wild-type and R6.58A(240) mutation, though a trend towards a mild increased 
potency in the mutant is suggested. The hGPR35 docks suggest a slight increase in the binding 
affinity for pamoic acid in the R6.58A(240) mutant, with a difference in the total protein-ligand 
EOI of -2.39 kcal/mol (Table 17). The GPR35 R6.58A(240) mutant and wild-type docks suggests 
these proteins have similar residue-protein EOIs for pamoic acid, with the major exception of the 
exchange of the primary interaction residue R6.58(240) for R7.32(255). In the wild-type dock, 
R6.58(240) is a primary interaction residue which forms a salt bridge with pamoic acid, with the 
resulting residue-ligand EOI of -12.97 kcal/mol. The mutation of arginine at position 6.58 to an 
alanine removes a primary interaction residue, though this removal allows for additional residue-
ligand interactions. In the R6.58A(240) mutant, the removal of the bulk of R6.58(240) allows for 
the juxtaposed residue R7.32(255) to form a nearly equivalent residue-ligand EOI with pamoic 
acid of -12.28 kcal/mol.  To achieve this near isoenergetic interchange of the residue R6.58(240)  
 
Table 17. The listed comparisons of the EOIs of pamoic acid docked (optimized) in the
human wild-type and R6.58A (240) human GPR35 minimized R* bundles. The displayed
residues are an inclusive list of residues that have a ≥ 2 kcal/mol residue-ligand EOI  
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with R7.32(255) in the mutant vs. wild-type dock, the position of pamoic acid shifted 
approximately 2Ǻ (measured from carbon linking the napthalene rings).  
The comparison of these docks suggests that the shift of pamoic acid changes multiple 
EOIs between the ligand and several residues on the EC2 loop. The most significant residue-
ligand EOI differences between pamoic acid and residues found in the EC2 loop occur at the 
residues F(163) and S(165).  The residue-ligand EOI differences (Table 17) of these residues in 
the R6.58A(240) mutant as compared to the wild-type shows a diminished interaction with 
F(163) and a improved EOI with S(165), with respective differences of +2.73 kcal/mol and -4.47 
kcal/mol. The net difference of approximately -2 kcal/mol of these residue-ligand EOI account 
for the majority of the total protein-ligand difference of -2.39 kcal/mol favoring the R6.58A(240) 
mutant.   
In summary, the potency of pamoic acid is not statistically significantly different between 
the hGPR35 wild-type and R6.58A(240) mutant, though there is a trend which suggest the mutant 
may have a slight increased potency to pamoic acid. These results parallel the differences in the 
protein-ligand EOI, which shows a -2.39 kcal/mol difference in the mutant as compared to the 
wild-type. These results suggest that the loss of the bulk of the primary wild-type interaction 
residue R6.58(240) in the R6.58A(240) mutant allows for the nearly isoenergetically exchange of 
R6.58(240) with the juxtaposed residue R7.32(255). This interchange of primary interaction 
residues causes a shift of pamoic acid of approximately 2 Å, affecting the residue-ligand EOIs 
between the ligand and several EC2 loop residues. The variance in the EOIs of the EC2 loop 
residues accounts for the majority of the difference of -2.39 kcal/mol in the mutant as compared 
to the wild-type.   
The ligand zaprinast has shown to have a statistically significant difference in potency in 
hGPR35 wild-type vs. R6.58A mutant, with respective EC50 values of 2.8 µM (0.5 – 15) and 0.08 
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µM (0.02 – 0.3) (Mary Abood, Unpublished Data). These potency differences correlate with the 
differences in the measured total protein-ligand EOI, which has an improved, lower EOI of -4.41 
kcal/mol in the R6.58A mutant dock. In the GPR35 wild-type dock the residue R6.58(240) 
interacts positively via Van der Waal forces with zaprinast, with a -2.06 kcal/mol residue-ligand 
EOI. Though this is a positive interaction, the position of R6.58(240) creates a barrier for 
zaprinast, therefore dictating its location and consequently limiting its possible interactions. In the 
R6.58A(240) mutant the positive R6.58(240) EOI is lost, but the removal of the bulk of this 
residue allows for a position change of zaprinast, leading to additional/improved residue-ligand 
interactions.  
The total EOI divergence can be mostly attributed to a small number of residue-ligand 
EOI differences, involving the residues Q3.29(93), Y3.32(96), F5.47(180), R7.32(255), and 
S7.39(262). The position change of zaprinast in the R6.58A(240) mutation improves the Van der 
Waal interaction of Q3.29(93) and Y3.32(96) in the R6.58A(240) mutant as compared to wild-
type, with respective EOI value differences of -1.25 and -1.55 kcal/mol. The shift in the ligand 
position also mitigates the residue-ligand EOI in the mutant between zaprinast and F5.47(180), 
with an EOI difference of 0.88 kcal/mol.  Additionally, a hydrogen bond and a cation-π 
interaction are gained in the mutant at the respective residues S7.39(262) and R7.32(255), with 
the coordinated EOI value differences of -1.84 and -1.24 kcal/mol. Noted is that the distance and 
angle of the cation-π interaction between R7.32(262) and the propoxy-benzyl functional group of 
Zaprinast are similar to the suggested ideal values. The EOI at the ideal distance/angle, as 
calculated at the MP2/6-31+G* level of theory, for the analogous molecules of benzene and N-
methyl guanidine is -13.96 kcal/mol [97]. The EOI between the residue R7.32(255) and zaprinast, 
as calculated by the OPLS2005 force field, was -1.24 kcal/mol, which diverges substantially from 
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the -13.96 kcal/mol calculated for the abovementioned analogous molecules, suggesting that this 
interaction may be more significant than the current parameters indicate.    
In summary, the statistically significant, approximately 35 fold increase in ligand potency 
of zaprinast in the hGPR35 R6.58A(240) mutant as compared to wild-type is paralleled by the 
difference in the measured protein-ligand EOI, which favors the mutant by -4.41 kcal/mol (Table 
18). The removal of the bulk of R6.58(240) in the R6.58A(240) mutation allows for improved 
and additional residue interactions with zaprinast. There are numerous differences in the residue-
ligand interactions that caused the improved protein-ligand EOI in the mutant dock, with the most 
notable differences being: the hydrogen bond with zaprinast and S7.39(262), the cation-π 
interaction with the ligand and R7.32(255), and the improved Van der Waals interactions with 
zaprinast and the residues Q3.29(93) and Y3.32(96).  
 
Table 18. The comparison of the EOIs of Zaprinast docked in the human wild-type and the R6.58A 
(240) mutant R* GPR35 bundles. The displayed residues are an inclusive list of residues that have a 
≥ 0.75 kcal/mol residue-ligand EOI difference. 
 
 
 
As discussed earlier, the mutation of R4.60(151) to alanine yielded ambiguous results. In 
this mutation, though it showed surface expression, both the agonists zaprinast and pamoic acid, 
were unable to elicit a response via a β2-arrestin assay or an ERK activity assay, (Abood, Mary. 
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Unpublished data). These data suggest that R4.60(151) is involved with protein folding, ligand 
binding, and or receptor activation. In the hGPR35 R*-pamoic acid docks, R4.60(151) forms a 
cation-π interaction with the ligand, which suggests that it is a primary interaction residue for this 
ligand. While this supports the inactivity of pamoic acid in the R4.60A(151) mutant, this does not 
offer a explanation for the effects on zaprinast. In the hGPR35-zaprinast docks R4.60A(151) is 
not suggested to have any interaction with the ligand, yet this mutation eliminates all zaprinast-
induced signaling. The GPR35 models offer two practical explanations for this possible 
inconsistency. In the GPR35 models the residue R4.60(151) sits directly in the TMH3-4-5 
interface, and is surrounded by multiple hydrophobic residues, including F5.42(175), L3.33(97), 
L4.57(148), and P5.43(176). The mutation of this large, charged residue to an alanine would 
create an energetically-unfavorable, large hole which would be filled by the surrounding residues 
or by water. As there are no adjacent residues in which a rotamer change would fill this gap, it is 
possible that the intracellular tops of TMH3, 4, and or 5 may adjust to maximize the hydrophobic 
interactions of the aforementioned residues- eliminating the hole, but collapsing the intracellular 
portion of the binding pocket. Additional support for the collapse of the binding pocket lies in the 
recruitment of water. With the charged R4.60(151) supplanted with the neutral alanine, the 
binding pocket would be become less hydrophilic, which would likely reduce the average number 
of waters in this channel. The lack of water in this area will lead to an even larger hole that is 
suggested by just the removal of the arginine, making the collapsing of the binding pocket more 
energetically favorable.       
 The fundamental goal of this project was to be able to ascertain viable reasons for the 
differences in the pharmacology of the ligands pamoic acid and zaprinast in rat wild-type, human 
wild-type, and in engineered human GPR35 mutants. The current models offer feasible 
explanations for the current known pharmacology of these ligands and additional mutational 
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studies are forthcoming to test the validity of these predictions.  Currently, the suggested direct 
interaction residues with the ligand pamoic acid are being used to steer the development of novel 
molecules. There are multiple goals actuating the engineering these novel molecules. The 
development of molecule with a high enough affinity for GPR35 can act as a radiolabel which 
would be instrumental in the understanding of this misunderstood GPCR. There are a multitude 
of ligands that are thought to act at GPR35, but the development of a radioligand would allow for 
the reassessment of many of these ligands, potentially leading to a better understanding of the 
currently convoluted purpose of GPR35 in vivo. The other major goal would be develop 
patentable pharmaceutics, both agonists and antagonists that are specific to GPR35. The extensive 
range of GPR35’s proposed involvement in vivo make this a potentially invaluable receptor to 
target, as it has associations with a nearly innumerable number of diseases and disorders. 
Additionally, the knowledge gained during the development of this novel receptor, which has the 
unusual quality of having multiple charged residues within the binding pocket, will hopefully 
translate to other similar GPCRs.          
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